<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1 20151215//EN" "https://jats.nlm.nih.gov/publishing/1.1/JATS-journalpublishing1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" specific-use="sps-1.9" dtd-version="1.1" xml:lang="pt" article-type="case-report">
  <front>
    <journal-meta>
      <journal-id journal-id-type="publisher-id">abc</journal-id>
      <journal-title-group>
        <journal-title>Arquivos Brasileiros de Cardiologia</journal-title>
        <abbrev-journal-title abbrev-type="publisher">Arq. Bras. Cardiol.</abbrev-journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0066-782X</issn>
      <issn pub-type="epub">1678-4170</issn>
      <publisher>
        <publisher-name>Sociedade Brasileira de Cardiologia - SBC</publisher-name>
        <publisher-loc>S&#227;o Paulo, SP, Brazil</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="publisher-id" specific-use="scielo-v3">kZwk65sDk35xP6VVx4HqGfS</article-id>
      <article-id pub-id-type="other">00020</article-id>
      <article-id pub-id-type="publisher-id" specific-use="scielo-v2">S0066-782X2009001100020</article-id>
      <article-id pub-id-type="publisher-id" specific-use="scielo-v1">S0066-782X(09)09300520</article-id>
      <article-id pub-id-type="doi">10.1590/S0066-782X2009001100020</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Correla&#231;&#227;o Anatomocl&#237;nica</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Caso 5: mulher de 50 anos com cardiomiopatia restritiva, insufici&#234;ncia renal e protein&#250;ria</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Silvestre</surname>
            <given-names>Odilson Marcos</given-names>
          </name>
          <xref ref-type="aff" rid="aff01"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Ribeiro</surname>
            <given-names>Henrique Barbosa</given-names>
          </name>
          <xref ref-type="aff" rid="aff01"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Paula</surname>
            <given-names>Leonardo Jorge C. de</given-names>
          </name>
          <xref ref-type="aff" rid="aff01"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Mac&#234;do</surname>
            <given-names>S&#233;rgio Ricardo V.</given-names>
          </name>
          <xref ref-type="aff" rid="aff01"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Castelli</surname>
            <given-names>Jussara Bianchi</given-names>
          </name>
          <xref ref-type="aff" rid="aff01"/>
        </contrib>
      </contrib-group>
      <aff id="aff01">
        <addr-line>
          <named-content content-type="city">S&#227;o Paulo</named-content>
          <named-content content-type="state">S&#227;o Paulo</named-content>
        </addr-line>
        <institution content-type="orgname">Universidade de S&#227;o Paulo</institution>
        <institution content-type="orgdiv1">FM </institution>
        <institution content-type="orgdiv2">HC</institution>
        <country country="BR">Brazil</country>
      </aff>
      <pub-date date-type="collection" publication-format="electronic">
        <month>11</month>
        <year>2009</year>
      </pub-date>
      <volume>93</volume>
      <issue>5</issue>
      <fpage>569</fpage>
      <lpage>577</lpage>
      <permissions>
        <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc/4.0/" xml:lang="en">
          <license-p>This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.</license-p>
        </license>
      </permissions>
      <kwd-group xml:lang="pt" kwd-group-type="author-generated">
        <kwd>Amiloidose</kwd>
        <kwd>cardiomiopatia restritiva</kwd>
        <kwd>choque cardiog&#234;nico</kwd>
        <kwd>embolia pulmonar</kwd>
      </kwd-group>
      <pub-date publication-format="electronic" date-type="pub">
        <day>11</day>
        <month>01</month>
        <year>2010</year>
      </pub-date>
    </article-meta>
  </front>
  <body>
    <p>
      <bold>CORRELA&#199;&#195;O ANATOMO-CL&#205;NICA</bold>
    </p>
    <p>Caso 5 - mulher de 50 anos com cardiomiopatia restritiva, insufici&#234;ncia renal e protein&#250;ria</p>
    <p>
      <bold>Odilson Marcos Silvestre; Henrique Barbosa Ribeiro; Leonardo Jorge C. de Paula; S&#233;rgio Ricardo V. Mac&#234;do; Jussara Bianchi Castelli</bold>
    </p>
    <p> Instituto do Cora&#231;&#227;o (InCor) HC-FMUSP, S&#227;o Paulo, SP - Brasil</p>
    <p>
      <xref ref-type="corresp" rid="end">Correspond&#234;ncia</xref>
    </p>
    <p><bold>Palavras-chave:</bold> Amiloidose, cardiomiopatia restritiva, choque cardiog&#234;nico, embolia pulmonar.</p>
    <p>Mulher de 50 anos de idade, natural de Pernambuco e procedente de S&#227;o Paulo, procurou atendimento m&#233;dico por dispneia desencadeada por esfor&#231;os pequenos.</p>
    <p> H&#225; 4 meses houve aparecimento de dispneia desencadeada por m&#233;dios esfor&#231;os, que h&#225; 2 meses progrediu para m&#237;nimos esfor&#231;os e ortopneia. Al&#233;m disso, apresentou edema de membros inferiores. Procurou atendimento m&#233;dico, recebeu o diagn&#243;stico de insufici&#234;ncia card&#237;aca e foi internada para tratamento. Paciente sabia ser portadora de hipotireoidismo h&#225; anos.</p>
    <p> Durante a interna&#231;&#227;o foi submetida &#224; toracocentese para drenagem de derrame pleural. A an&#225;lise bioqu&#237;mica do l&#237;quido pleural (6 Dez 2007) revelou desidrogenase l&#225;tica (DHL) (derrame pleural/soro) 104/216 = 0,48; prote&#237;na (derrame pleural/soro) 2,8/6,2 = 0,45; gradiente de albumina = 1,5. </p>
    <p>A paciente recebeu alta hospitalar com prescri&#231;&#227;o de 80 mg de furosemida, 50 mg de espironolactona, 75 mg de captopril, 100 &#181;g de levotiroxina diariamente al&#233;m de 0,25 mg em dias alternados de digoxina.</p>
    <p> Embora diante da melhora da dispneia, depois da alta a paciente apresentou nova piora do quadro com dispneia aos esfor&#231;os menores que os habituais e procurou atendimento neste Hospital.</p>
    <p> O exame f&#237;sico (9 Jan 2008) revelou paciente eupneica, com aumento da press&#227;o venosa jugular, frequ&#234;ncia card&#237;aca de 100 bpm e press&#227;o arterial 90/80 mm Hg. O exame dos pulm&#245;es revelou diminui&#231;&#227;o de murm&#250;rio vesicular em ter&#231;o m&#233;dio do hemit&#243;rax direito e aboli&#231;&#227;o em ter&#231;o inferior de ambos os hemit&#243;rax. A semiologia card&#237;aca revelou 4&#170; bulha, n&#227;o havia sopros ou atrito peric&#225;rdico. O abdome era doloroso&#224; percuss&#227;o e palpa&#231;&#227;o de hipoc&#244;ndrio direito. O f&#237;gado foi palpado a 10 cm da reborda costal direita; havia edema +++/4+ em membros inferiores.</p>
    <p>A radiografia de t&#243;rax (9 Jan 2008) revelou grande derrame pleural bilateral.</p>
    <p> O ECG (14 Jan 2008) revelou ritmo sinusal, frequ&#234;ncia card&#237;aca 100 bpm, sobrecarga atrial esquerda, sinais indiretos de sobrecarga atrial direita (Pe&#241;aloza-Tranchesi), baixa voltagem do QRS no plano frontal, onda R pouco progressiva de V<sub>1</sub> a V<sub>4</sub> (<xref ref-type="fig" rid="fig01">Figura 1</xref>). </p>
    <fig id="fig01">
      <graphic xlink:href="1678-4170-abc-93-05-0569-00020-gf01.jpg"/></fig>
    <p>Os exames de laborat&#243;rio (9 Jan 2008) revelaram eleva&#231;&#227;o da creatinina (<xref ref-type="table" rid="tab01">Tabela 1</xref>).</p>
    <table-wrap id="tab01">
      <graphic xlink:href="1678-4170-abc-93-05-0569-00020-gt01.jpg"/></table-wrap>
    <p> O ecocardiograma (10 Jan 2008) revelou: aorta 29 mm, &#225;trio esquerdo 41 mm, di&#226;metro diast&#243;lico de ventr&#237;culo direito 29 mm, dimens&#245;es do ventr&#237;culo esquerdo (di&#225;stole/ s&#237;stole) 38 mm/28 mm, espessuras de septo interventricular e parede posterior de 13 mm e fra&#231;&#227;o de eje&#231;&#227;o de ventr&#237;culo esquerdo de 52%. Foi feito o diagn&#243;stico de hipertrofia conc&#234;ntrica de grau moderado. Havia hiper-refring&#234;ncia do septo interventricular. A fun&#231;&#227;o ventricular sist&#243;lica estava diminu&#237;da &#224; custa de hipocinesia difusa. Os achados do Doppler foram compat&#237;veis com padr&#227;o restritivo sem revers&#227;o ap&#243;s manobra de Valsalva. O ventr&#237;culo direito demonstrou hipertrofia discreta e hipocinesia moderada e havia insufici&#234;ncia tric&#250;spide acentuada.</p>
    <p> Foram realizadas pun&#231;&#227;o e drenagem de derrame pleural e institu&#237;da terap&#234;utica para insufici&#234;ncia card&#237;aca, com uso de furosemida por via endovenosa e manuten&#231;&#227;o das medica&#231;&#245;es em uso.</p>
    <p> Nova avalia&#231;&#227;o do l&#237;quido pleural (16 jan 08) revelou as raz&#245;es de DHL (derrame pleural/soro) 120/210 = 0,57; prote&#237;nas (derrame pleural/soro) 3,6/6,7=0,54; gradiente de albumina= 1.2, 440 leuc&#243;citos/mm&#179;, colesterol &lt;50 mg/dl, glicose 119 mg/dl</p>
    <p> A ultrassonografia de abdome (14 Jan 08) revelou &#225;rea hiperecog&#234;ncia em lobo hep&#225;tico, cujo aspecto ultrassonogr&#225;fico era compat&#237;vel com hemangioma; al&#233;m de ascite de pequeno volume e derrame pleural bilateral. N&#227;o havia outras altera&#231;&#245;es.</p>
    <p> A ultrassonografia de via urin&#225;rias (22 Jan 2008) foi normal.</p>
    <p> A tomografia de t&#243;rax (17 Jan 2008) revelou volumoso derrame pleural bilateral com atelectasia dos lobos inferiores e dos segmentos posteriores dos lobos superiores. </p>
    <p>Apesar da melhora da dispneia houve persist&#234;ncia do derrame pleural &#224; direita e progressiva piora da fun&#231;&#227;o renal (<xref ref-type="table" rid="tab01">Tab. 1</xref>), com paciente mantendo sempre press&#227;o arterial de 90/60 mm Hg. Foram suspensos os diur&#233;ticos, captopril e digoxina e iniciado o uso de dobutamina; foi indicada hemodi&#225;lise e a paciente foi transferida para unidade de terapia intensiva..</p>
    <p>A bi&#243;psia de pele (16 jan 08) foi negativa para subst&#226;ncia amiloide (colora&#231;&#227;o vermelho-Congo).</p>
    <p>Na noite de 27 de janeiro de 2008 apresentou parada card&#237;aca em atividade el&#233;trica sem pulso que foi recuperada. A paciente evoluiu hipotensa. Foi realizado novo ecocardiograma para descartar tamponamento card&#237;aco, o qual revelou ventr&#237;culo esquerdo com hipertrofia conc&#234;ntrica de grau discreto e hiper-refring&#234;ncia do septo, sugestiva de processo infiltrativo, e fun&#231;&#227;o sist&#243;lica diminu&#237;da &#224; custa de hipocinesia difusa. O ventr&#237;culo direito tinha hipocinesia acentuada e derrame peric&#225;rdico de grau discreto a moderado</p>
    <p>Foi realizada pun&#231;&#227;o tor&#225;cica &#224; direita e n&#227;o havia sinais de hemot&#243;rax. A radiografia de t&#243;rax ap&#243;s os cateteres centrais n&#227;o revelaram pneumot&#243;rax. Cerca de uma hora ap&#243;s a parada card&#237;aca inicial houve nova parada em atividade el&#233;trica sem pulso, esta irrevers&#237;vel (27 Jan 2008).</p>
    <p>
      <bold>Aspectos cl&#237;nicos</bold>
    </p>
    <p>O caso descrito refere-se a uma mulher de 50 anos de idade com hist&#243;ria de hipotireoidismo, que apresentou dispneia progressiva nos &#250;ltimos quatro meses a despeito do tratamento para insufici&#234;ncia card&#237;aca.</p>
    <p>A insufici&#234;ncia card&#237;aca (IC) constitui diagn&#243;stico cl&#237;nico feito pela compila&#231;&#227;o de dados da anamnese e exame f&#237;sico<sup>1</sup>. A hist&#243;ria cl&#237;nica da IC caracteriza-se por dispneia ou cansa&#231;o aos esfor&#231;os. Ortopneia e dispneia parox&#237;stica noturna s&#227;o achados mais espec&#237;ficos para o diagn&#243;stico desta s&#237;ndrome. Ressalta-se a import&#226;ncia da busca de fatores de risco ou de doen&#231;a cardiovascular pr&#233;via. O exame f&#237;sico tem maior contribui&#231;&#227;o na IC descompensada, j&#225; que a sensibilidade &#233; baixa quando est&#225; compensada. As altera&#231;&#245;es s&#227;o relacionadas &#224; congest&#227;o ou &#224; cardiomegalia, al&#233;m de achados que podem sugerir a etiologia da doen&#231;a card&#237;aca. Dessa forma, edema perif&#233;rico, taquicardia em repouso, estertores pulmonares, turg&#234;ncia venosa jugular, refluxo hepatojugular, hepatomegalia, &#237;ctus desviado e bulhas acess&#243;rias devem ser procurados na avalia&#231;&#227;o proped&#234;utica. Doen&#231;a valvar ou peric&#225;rdica podem ser denunciadas pela presen&#231;a de sopros ou &#8220;knock&#8221; peric&#225;rdico, respectivamente<sup>2</sup>.</p>
    <p>A paciente em quest&#227;o tem hist&#243;ria de dispneia relacionada aos esfor&#231;os que progrediu no decorrer do tempo, culminando com sintomas aos m&#237;nimos esfor&#231;os, ortopneia e necessidade de interna&#231;&#227;o. &#201; importante ressaltar que n&#227;o h&#225; descri&#231;&#227;o de fatores de risco cardiovasculares nem doen&#231;a card&#237;aca pr&#233;via. O exame f&#237;sico mostrou importantes achados para o diagn&#243;stico da s&#237;ndrome e tamb&#233;m dados para o in&#237;cio da reflex&#227;o sobre a etiologia da IC. A presen&#231;a de taquicardia no repouso &#233; um achado comum, mas de pouca especificidade para o diagn&#243;stico. N&#227;o h&#225; descri&#231;&#227;o do &#237;ctus card&#237;aco, dado de import&#226;ncia diagn&#243;stica inquestion&#225;vel. O relato de turg&#234;ncia venosa jugular, hepatomegalia e edema perif&#233;rico nos levam a pensar em congest&#227;o sist&#234;mica, ou seja, insufici&#234;ncia card&#237;aca direita. Deve-se ressaltar que a presen&#231;a de turg&#234;ncia venosa jugular e press&#227;o de pulso diminu&#237;da (PA 90 x 80 mmHg) determinam pior progn&#243;stico ao caso. A presen&#231;a da quarta bulha sugere disfun&#231;&#227;o diast&#243;lica do mioc&#225;rdio. Vale lembrar que a hepatomegalia acentuada pode sugerir, al&#233;m da congest&#227;o, infiltra&#231;&#227;o do tecido hep&#225;tico. Os achados da proped&#234;utica mostram ainda a exist&#234;ncia de derrame pleural bilateral, principalmente &#224; direita, assim como ocorre geralmente na IC. Provavelmente o derrame tenha colaborado para o surgimento da dispneia. A an&#225;lise do l&#237;quido pleural foi realizada em dois momentos. No in&#237;cio da interna&#231;&#227;o, a primeira an&#225;lise &#224; luz dos crit&#233;rios de Light caracterizou o l&#237;quido como transudato, o que corrobora a afirmativa de derrame secund&#225;rio &#224; IC. J&#225; na segunda pun&#231;&#227;o, o l&#237;quido tem par&#226;metros que sugerem exsudato, mas vale lembrar que neste momento a paciente estava em uso de diur&#233;ticos, o que pode explicar a modifica&#231;&#227;o bioqu&#237;mica do l&#237;quido.</p>
    <p>Os dados de anamnese e exame f&#237;sico possibilitam o diagn&#243;stico sindr&#244;mico de IC. Por&#233;m a hist&#243;ria cl&#237;nica n&#227;o mostra dados que possam sugerir a etiologia, pois n&#227;o h&#225; relato de hipertens&#227;o, doen&#231;a isqu&#234;mica ou mesmo fatores de risco cardiovasculares. O exame f&#237;sico nos mostra um predom&#237;nio de achados compat&#237;veis com IC direita.</p>
    <p>Na an&#225;lise dos exames complementares, a radiografia de t&#243;rax confirmou a presen&#231;a de grande derrame pleural bilateral, mas n&#227;o houve relato do tamanho da &#225;rea card&#237;aca.</p>
    <p>Os exames laboratoriais da admiss&#227;o mostraram aus&#234;ncia de altera&#231;&#227;o consistente nas s&#233;ries hematol&#243;gicas. A dosagem de horm&#244;nios tireoidianos evidenciou que o hipotireoidismo estava compensado. A fun&#231;&#227;o renal esteve alterada desde o in&#237;cio, sempre com uma rela&#231;&#227;o ureia: creatinina &gt; 40, sugerindo padr&#227;o pr&#233;-renal. Contudo, a presen&#231;a de protein&#250;ria patol&#243;gica na urina de 24 horas sugere doen&#231;a do par&#234;nquima renal. O aumento progressivo das esc&#243;rias nitrogenadas possivelmente esteve relacionado ao uso de diur&#233;ticos durante a interna&#231;&#227;o.</p>
    <p>O eletrocardiograma inicial mostrava sinais de sobrecarga biatrial, baixa voltagem do QRS no plano frontal, al&#233;m de onda R que pouco progredia de V1 a V4. Dentre as condi&#231;&#245;es que cursam com baixa voltagem do QRS temos derrame peric&#225;rdico, doen&#231;a pulmonar obstrutiva cr&#244;nica e hipotireoidismo. Todavia nenhuma delas justifica aumento da massa card&#237;aca que foi detectada pelo ecocardiograma transtor&#225;cico (ETT). Soma-se a isso aus&#234;ncia de derrame peric&#225;rdico ao ETT, aus&#234;ncia de antecedente de doen&#231;a pulmonar obstrutiva cr&#244;nica, bem como TSH e T4 livre normais. Por outro lado, o aumento da massa mioc&#225;rdica, em fun&#231;&#227;o de condi&#231;&#245;es como hipertens&#227;o ou cardiomiopatia hipertr&#243;fica, associa-se a voltagem normal ou aumentada no eletrocardiograma, o que n&#227;o foi observado em nosso caso. Deste modo, a presen&#231;a de hipertrofia ao ETT, associada &#224; baixa voltagem eletrocardiogr&#225;fica s&#227;o achados exclusivos das doen&#231;as mioc&#225;rdicas infiltrativas<sup>3, 4</sup>.</p>
    <p>A amiloidose em at&#233; 50% dos pacientes pode determinar ao ECG baixa voltagem do QRS em deriva&#231;&#245;es de membros<sup>4, 5</sup>. Outra altera&#231;&#227;o muito frequente nessa doen&#231;a &#233; a presen&#231;a de padr&#227;o de pseudoinfarto. Tanto na amiloidose, quanto nas demais doen&#231;as infiltrativas do cora&#231;&#227;o, como a hemocromatose, sarcoidose ou doen&#231;a de Fabry, s&#227;o comuns os dist&#250;rbios de condu&#231;&#227;o, muitas vezes com bloqueios avan&#231;ados, o que n&#227;o foi verificado em nosso caso. Al&#233;m disso, essas referidas doen&#231;as tamb&#233;m cursam com fibrila&#231;&#227;o atrial parox&#237;stica ou persistente, especialmente a amiloidose e a doen&#231;a de Fabry, o que tamb&#233;m n&#227;o pudemos observar.</p>
    <p>As doen&#231;as infiltrativas mioc&#225;rdicas em seu in&#237;cio levam a disfun&#231;&#227;o diast&#243;lica associada &#224; hipertrofia de parede, sendo que a disfun&#231;&#227;o diast&#243;lica de ventr&#237;culo direito tamb&#233;m pode ocorrer<sup>6</sup>. Em casos mais avan&#231;ados, a hipertrofia de parede progride, resultando em cardiomiopatia restritiva, com cavidade ventricular esquerda n&#227;o dilatada e pequena<sup>6</sup>. Esse padr&#227;o, aliado ao aumento biatrial s&#227;o tamb&#233;m mais frequentes na amiloidose, j&#225; que na sarcoidose, e especialmente na hemocromatose, a dilata&#231;&#227;o do ventr&#237;culo esquerdo &#233; mais prevalente. </p>
    <p>Outros fatores importantes obtidos para o diagn&#243;stico diferencial a partir do ETT s&#227;o a presen&#231;a de mioc&#225;rdio &#8220;cintilante&#8221;, e aus&#234;ncia de valvopatia importante (apenas espessamento das c&#250;spides) que est&#227;o presentes na amiloidose. O mioc&#225;rdio cintilante &#233; um achado pouco sens&#237;vel (26% em uma s&#233;rie) e n&#227;o pode ser utilizado para descartar a amiloidose<sup>4</sup>. Por outro lado, a dilata&#231;&#227;o do ventr&#237;culo direito, al&#233;m de ser considerada progn&#243;stica na amiloidose, aliada ao aumento das press&#245;es de enchimento, justifica a insufici&#234;ncia tric&#250;spide muitas vezes presente, como em nosso caso. Outras doen&#231;as infiltrativas mioc&#225;rdicas, como a sarcoidose e a doen&#231;a de Fabry podem cursar com valvopatia especialmente mitral e a&#243;rtica<sup>6</sup>.</p>
    <p>Frente aos dados apresentados at&#233; o momento, consideramos a amiloidose como principal hip&#243;tese. Essa consiste em um grupo heterog&#234;neo de desordens heredit&#225;rias, inflamat&#243;rias, ou neopl&#225;sicas, que resultam em dep&#243;sitos de fibrilas amiloides em diversos &#243;rg&#227;os, tais como cora&#231;&#227;o, rins e sistema nervoso. As fibrilas amiloides s&#227;o consideradas subunidades proteicas de baixo peso molecular derivadas de prote&#237;nas s&#233;ricas normais ou aberrantes<sup>7</sup>. O acometimento card&#237;aco deve-se &#224; infiltra&#231;&#227;o mioc&#225;rdica dessas prote&#237;nas, por mecanismos patog&#234;nicos diferentes, tornando-se clinicamente aparente quando o dep&#243;sito extracelular de amiloide altera a arquitetura do tecido normal<sup>7</sup>.</p>
    <p>Nas doen&#231;as infiltrativas, muitas vezes a etiologia &#233; confirmada pela bi&#243;psia endomioc&#225;rdica. Isso pode acontecer, por exemplo, pela colora&#231;&#227;o com vermelho-Congo dos dep&#243;sitos amiloides, na amiloidose; granulomas sarco&#237;dicos, na sarcoidose; e corp&#250;sculos lamelares na doen&#231;a de Fabry. Todavia, a bi&#243;psia endomioc&#225;rdica apresenta complica&#231;&#245;es e muitas vezes n&#227;o pode ser realizada. Nesse sentido, outras modalidades diagn&#243;sticas devem ser utilizadas. No caso da amiloidose isso pode ser realizado pela demonstra&#231;&#227;o de dep&#243;sitos amiloides no exame histopatol&#243;gico de bi&#243;psias colhidas de tecidos como gordura abdominal, reto ou dos rins. Nessa paciente, o tecido celular subcut&#226;neo foi colhido, todavia resultou negativo para subst&#226;ncia amiloide. Em trabalhos retrospectivos a sensibilidade do exame &#233; bastante alta, especialmente quando v&#225;rias amostras s&#227;o utilizadas (aproxima-se de 100% quando pelo menos 4 amostras s&#227;o realizadas)<sup>8</sup>.</p>
    <p>Outro exame bastante elucidativo nas cardiopatias infiltrativas &#233; a resson&#226;ncia nuclear magn&#233;tica que, neste caso, n&#227;o h&#225; descri&#231;&#227;o de sua realiza&#231;&#227;o, possivelmente pela disfun&#231;&#227;o renal apresentada, com risco de evolu&#231;&#227;o para fibrose nefrog&#234;nica sist&#234;mica.</p>
    <p>Em resumo, temos o caso de uma paciente do sexo feminino de 50 anos, sem hist&#243;ria pr&#233;via de doen&#231;a cardiovascular ou comorbidades conhecidas, que evoluiu para dispneia rapidamente progressiva chegando at&#233; m&#237;nimos esfor&#231;os, associada a ortopneia e congest&#227;o sist&#234;mica (aumento do volume hep&#225;tico e edema de membros inferiores). Apresentava sintomas inespec&#237;ficos, por&#233;m ao ETT foi evidenciada hipertrofia ventricular, hiper-refring&#234;ncia do septo ventricular e padr&#227;o restritivo ao Doppler, achados esses compat&#237;veis com processos infiltrativos mioc&#225;rdicos. Frente &#224; apresenta&#231;&#227;o cl&#237;nica, altera&#231;&#245;es eletrocardiogr&#225;ficas e ecocardiogr&#225;ficas, presen&#231;a de protein&#250;ria e hepatomegalia, a amiloidose torna-se a principal hip&#243;tese diagn&#243;stica. Contudo, outras doen&#231;as infiltrativas mioc&#225;rdicas tamb&#233;m devem ser investigadas, em fun&#231;&#227;o dos sintomas apresentados e especialmente pelo fato de a bi&#243;psia de tecido celular subcut&#226;neo ter sido negativa.</p>
    <p>As doen&#231;as infiltrativas mioc&#225;rdicas s&#227;o classificadas no grupo das cardiopatias restritivas, sendo essas caracterizadas pela rigidez das paredes mioc&#225;rdicas associadas &#224; n&#227;o-complac&#234;ncia de um ou de ambos os ventr&#237;culos, sendo mais comum o envolvimento do ventr&#237;culo esquerdo, levando a enchimento ventricular inadequado e consequente aumento da press&#227;o diast&#243;lica final<sup>9</sup>.</p>
    <p>Esse grupo de cardiomiopatias se divide em tr&#234;s classes distintas entre si: </p>
    <p>1) as infiltra&#231;&#245;es mioc&#225;rdicas, na qual o mioc&#225;rdio &#233; infiltrado por uma subst&#226;ncia anormal (como na amiloidose, sarcoidose, hemocromatose e doen&#231;a de Fabry); </p>
    <p>2) as afec&#231;&#245;es fibr&#243;ticas do mioc&#225;rdio, com extens&#227;o fibrosa por toda a parede mioc&#225;rdica (cardiomiopatia familiar e idiop&#225;tica); </p>
    <p>3) as afec&#231;&#245;es fibr&#243;ticas endomioc&#225;rdicas, na qual h&#225; acometimento principalmente do endoc&#225;rdio e sub-endoc&#225;rdio (endomiocardiofibrose (EMF), s&#237;ndrome hipereosinof&#237;lica e met&#225;stases de doen&#231;as tumorais)<sup>9</sup>.</p>
    <p>Entre as doen&#231;as infiltrativas do cora&#231;&#227;o devemos lembrar como diagn&#243;stico diferencial a sarcoidose card&#237;aca. Esta &#233; doen&#231;a sist&#234;mica, de etiologia desconhecida, que se caracteriza pela forma&#231;&#227;o de granulomas n&#227;o caseosos em qualquer &#243;rg&#227;o do corpo, levando a desarranjo das estruturas teciduais<sup>10</sup>. Geralmente, o diagn&#243;stico da doen&#231;a card&#237;aca &#233; feito alguns anos ap&#243;s o desenvolvimento de sintomas relacionados &#224; disfun&#231;&#227;o de outros &#243;rg&#227;os (pulm&#227;o, f&#237;gado, pele e olhos). Por&#233;m numa minoria de pacientes pode haver acometimento card&#237;aco puro, sem qualquer outra manifesta&#231;&#227;o da doen&#231;a<sup>11</sup>. O acometimento card&#237;aco ocorre em at&#233; 30% dos pacientes, apesar de apenas 5% deles manifestarem clinicamente a doen&#231;a, sendo esta caracterizada por bloqueios atrioventriculares avan&#231;ados e espessamento anormal da parede<sup>12-14</sup>. Quase a totalidade dos pacientes apresenta acometimento do trato respirat&#243;rio, manifestando-se com linfadenopatia hilar e infiltrado pulmonar intersticial. A linfadenopatia hilar acomete 90% dos indiv&#237;duos com a doen&#231;a. Dessa forma, a partir da apresenta&#231;&#227;o cl&#237;nica e radiol&#243;gica do paciente, o diagn&#243;stico pode ser suspeitado, por&#233;m a confirma&#231;&#227;o deve ser feita a partir de bi&#243;psia com demonstra&#231;&#227;o de granulomas n&#227;o caseosos<sup>15</sup>. </p>
    <p>Al&#233;m da disfun&#231;&#227;o card&#237;aca a paciente em quest&#227;o apresentava hepatomegalia com imagens hiperecog&#234;nicas semelhantes a hemangiomas. Na sarcoidose, raramente ocorre disfun&#231;&#227;o hep&#225;tica importante, por&#233;m pode haver discreto aumento de enzimas hep&#225;ticas e aumento mais importante de enzimas canaliculares, o que por vezes pode levar a sintomas de hipertens&#227;o portal<sup>10</sup>. Na evolu&#231;&#227;o do caso, frente &#224;s hip&#243;teses diagn&#243;sticas, poderia ter sido realizada bi&#243;psia hep&#225;tica ou mioc&#225;rdica, j&#225; que o achado de granulomas sela o diagn&#243;stico. Todavia, resultado falso negativo pode ocorrer devido ao fato de o acometimento n&#227;o ser homog&#234;neo, principalmente na afec&#231;&#227;o card&#237;aca<sup>16</sup>. O que fala contra o diagn&#243;stico de sarcoidose card&#237;aca na paciente &#233; a presen&#231;a de hiperrefring&#234;ncia do septo no ETT, pois na sarcoidose as altera&#231;&#245;es s&#227;o inespec&#237;ficas, podendo-se encontrar aneurisma ventricular, dilata&#231;&#227;o da cavidade e espessamento de parede<sup>17</sup>.</p>
    <p>Outro diagn&#243;stico diferencial poss&#237;vel &#233; a hemocromatose heredit&#225;ria. Ela se caracteriza como doen&#231;a autoss&#244;mica recessiva na qual a muta&#231;&#227;o no gene HEF causa aumento da absor&#231;&#227;o intestinal de ferro, levando a manifesta&#231;&#245;es cl&#237;nicas secund&#225;rias ao excesso de dep&#243;sito de ferro nos tecidos, especialmente f&#237;gado, cora&#231;&#227;o, p&#226;ncreas e hip&#243;fise<sup>18</sup>. A forma heterozigota da doen&#231;a normalmente n&#227;o se manifesta clinicamente durante a vida, podendo ser um achado a partir da dosagem da satura&#231;&#227;o da transferrina (raz&#227;o entre a concentra&#231;&#227;o de ferro s&#233;rico pela capacidade total de liga&#231;&#227;o ao ferro)<sup>19</sup>. J&#225; a forma homozigota pode levar a manifesta&#231;&#245;es graves da doen&#231;a, geralmente ap&#243;s os 40 anos de idade, sendo mais tardio no sexo feminino devido &#224;s perdas menstruais na fase pr&#233;-menopausa<sup>20, 21</sup>. As manifesta&#231;&#245;es mais frequentes s&#227;o altera&#231;&#245;es da fun&#231;&#227;o hep&#225;tica, letargia, hiperpigmenta&#231;&#227;o cut&#226;nea, diabetes mellitus e anormalidades eletrocardiogr&#225;ficas<sup>22</sup>. Os dist&#250;rbios card&#237;acos mais comuns s&#227;o a dilata&#231;&#227;o ventricular caracterizada pelo desenvolvimento de insufici&#234;ncia card&#237;aca e dist&#250;rbios de condu&#231;&#227;o<sup>23</sup>. A hipertrofia ventricular n&#227;o &#233; caracter&#237;stica, assim como a hiper-refring&#234;ncia ao ETT. No caso exposto, al&#233;m da disfun&#231;&#227;o card&#237;aca n&#227;o ser t&#237;pica, a dosagem s&#233;rica de ferro e ferritina eram normais, fatos esses que excluem o diagn&#243;stico.</p>
    <p>Na investiga&#231;&#227;o da paciente, um diagn&#243;stico menos prov&#225;vel, mas que deve ser lembrado &#233; a doen&#231;a de Fabry. &#201; uma doen&#231;a de dep&#243;sito de glicolip&#237;deos ligada ao cromossoma X e &#233; causada pela atividade deficiente da enzima lipossomal Alfa-galactosidase A, levando ao ac&#250;mulo e dep&#243;sito tissular subsequente de globotriaosylceramida<sup>24</sup>. Uma caracter&#237;stica importante &#233; que a manifesta&#231;&#227;o cl&#237;nica geralmente ocorre antes dos 10 anos de idade, incluindo les&#245;es cut&#226;neas e neuropatia perif&#233;rica, apesar de alguns estudos de rastreamento populacional evidenciarem seu in&#237;cio mais tardio (ap&#243;s os 40 anos de idade)<sup>25</sup>. Com rela&#231;&#227;o ao acometimento card&#237;aco, este pode levar a hipertrofia ventricular importante, defeitos de condu&#231;&#227;o, doen&#231;a arterial coronariana e insufici&#234;ncia das valvas a&#243;rtica e mitral. Por&#233;m, os principais sintomas s&#227;o de palpita&#231;&#245;es, angina do peito e dispneia, sendo muito incomuns sintomas importantes de fal&#234;ncia ventricular. Ressalta-se a presen&#231;a de acometimento card&#237;aco isolado em algumas muta&#231;&#245;es<sup>25, 26</sup>. Este fato explica a raz&#227;o de ser realizado o rastreamento da doen&#231;a em pacientes com hipertrofia ventricular isolada sem outra causa aparente. </p>
    <p>A investiga&#231;&#227;o inicial pode ser realizada com a demonstra&#231;&#227;o de baixos n&#237;veis de alfa-galactosidase A e o diagn&#243;stico confirmado com bi&#243;psia endomioc&#225;rdica evidenciando corpos lamelares conc&#234;ntricos no tecido sarcoplasm&#225;tico das c&#233;lulas<sup>24</sup>. De forma menos invasiva, o ETT pode distinguir a hipertrofia mioc&#225;rdica da doen&#231;a de Fabry de outras formas de hipertrofia ventricular, a partir da demonstra&#231;&#227;o de espessamento hiperecog&#234;nico do endoc&#225;rdio e sub-endoc&#225;rdio pela deposi&#231;&#227;o glicolip&#237;dica. Concomitantemente, h&#225; espessamento hipoecog&#234;nico em paralelo ao longo de todo o contorno mioc&#225;rdico, altera&#231;&#227;o essa chamada de apar&#234;ncia bin&#225;ria da borda endoc&#225;rdica do ventr&#237;culo<sup>27</sup>. No caso exposto, o padr&#227;o ecocardiogr&#225;fico n&#227;o se assemelha ao descrito para a doen&#231;a, assim como n&#227;o h&#225; hist&#243;ria familiar sabida de doen&#231;as ligadas ao cromossomo X ou hist&#243;ria familiar de hipertrofia ventricular, dados considerados de maior relev&#226;ncia para a realiza&#231;&#227;o de investiga&#231;&#227;o da doen&#231;a<sup>28</sup>.</p>
    <p>Com rela&#231;&#227;o &#224;s afec&#231;&#245;es fibr&#243;ticas endomioc&#225;rdicas como diagn&#243;stico diferencial do presente caso, devemos nos lembrar da endomiocardiofibrose, entidade de etiologia indefinida, prevalente na zona dos tr&#243;picos<sup>29</sup>. Caracteriza-se por envolvimento fibr&#243;tico do endoc&#225;rdio e mioc&#225;rdio adjacente, &#225;pice e via de entrada dos ventr&#237;culos. O processo fibr&#243;tico acomete frequentemente os m&#250;sculos papilares determinando disfun&#231;&#227;o das valvas atrioventriculares. Esse quadro gera restri&#231;&#227;o ao enchimento ventricular, ocasionando as manifesta&#231;&#245;es cl&#237;nicas e desordens hemodin&#226;micas sugestivas da doen&#231;a. Incide igualmente em ambos os sexos, tendo sido descrita em indiv&#237;duos dos 4 aos 70 anos, apesar de sua maior preval&#234;ncia em crian&#231;as e adultos jovens<sup>29</sup>.</p>
    <p>Clinicamente, o paciente com EMF pode se apresentar com manifesta&#231;&#245;es de IC direita, esquerda ou ambas, dependendo do grau de envolvimento dos ventr&#237;culos. Frequentemente ocorre insufici&#234;ncia de uma ou ambas as valvas atrioventriculares, pelo acometimento dos m&#250;sculos papilares. O in&#237;cio da doen&#231;a normalmente &#233; insidioso, raramente a doen&#231;a pode estabilizar, evoluindo com fal&#234;ncia mioc&#225;rdica progressiva. </p>
    <p>A oblitera&#231;&#227;o do &#225;pice do ventr&#237;culo envolvido ao ETT &#233; um ponto principal da doen&#231;a, al&#233;m de &#225;trios dilatados, com cavidades ventriculares normais ou discretamente dilatadas. Tamb&#233;m h&#225; espessamento da parede posterior ou septo ventricular anterior em pacientes com envolvimento do ventr&#237;culo esquerdo ou direito, respectivamente<sup>29</sup>. O ETT pode mostrar derrame peric&#225;rdico associado. A paciente do caso n&#227;o apresentava ETT compat&#237;vel com a descri&#231;&#227;o cl&#225;ssica da EMF, devido &#224; aus&#234;ncia de imagem de oblitera&#231;&#227;o dos &#225;pices ventriculares, al&#233;m de demonstrar espessamento difuso do septo, o que sugere doen&#231;a infiltrativa. Soma-se a isso faixa et&#225;ria pouco compat&#237;vel com o quadro.</p>
    <p>Na evolu&#231;&#227;o da paciente, apesar do tratamento cl&#237;nico para a IC, houve persist&#234;ncia dos sintomas, progressiva piora da fun&#231;&#227;o renal e hipotens&#227;o. A paciente foi transferida para a unidade de terapia intensiva, onde evoluiu com parada cardiorrespirat&#243;ria (PCR), em atividade el&#233;trica sem pulso (AESP). De forma geral, as poss&#237;veis causas da PCR em AESP s&#227;o: hipoxemia, hipovolemia, hipotermia, hipercalemia, acidose, hipoglicemia, infarto agudo do mioc&#225;rdio, tromboembolismo pulmonar, pneumot&#243;rax, tamponamento, drogas, trauma. O pot&#225;ssio dosado no dia da PCR era de 5,8 mg/dL, sendo que n&#227;o h&#225; descri&#231;&#227;o de gasometria ou glicemia. A investiga&#231;&#227;o feita com radiografia de t&#243;rax n&#227;o demonstrou pneumot&#243;rax, nem outras complica&#231;&#245;es advindas de procedimento m&#233;dico invasivo. O ETT mostrou as altera&#231;&#245;es j&#225; existentes, descartou tamponamento, mas evidenciou disfun&#231;&#227;o ventricular direita importante que havia sido descrita como moderada em ETT pr&#233;vio. Dessa forma, consideramos TEP com evolu&#231;&#227;o para choque a principal hip&#243;tese para a causa mortis. Contudo, a hipercalemia, apesar de n&#227;o t&#227;o importante, tamb&#233;m n&#227;o pode ser descartada como fator decisivo. </p>
    <p>Dr. Odilson Marcos Silvestre </p>
    <p> Dr. Henrique Barbosa Ribeiro </p>
    <p> Dr. Leonardo Jorge C. de Paula </p>
    <p> Dr. S&#233;rgio Ricardo V. Macedo</p>
    <p><bold>Hip&#243;tese diagn&#243;stica: </bold>amiloidose sist&#234;mica com acometimento hep&#225;tico, renal e card&#237;aco, determinando disfun&#231;&#227;o mioc&#225;rdica direita e esquerda; choque cardiog&#234;nico; tromboembolismo pulmonar. </p>
    <p>Dr. Odilson Marcos Silvestre </p>
    <p> Dr. Henrique Barbosa Ribeiro </p>
    <p> Dr. Leonardo Jorge C. de Paula </p>
    <p> Dr. S&#233;rgio Ricardo V. Macedo</p>
    <p>
      <bold>Necr&#243;psia</bold>
    </p>
    <p>Na necr&#243;psia, o cora&#231;&#227;o apresentava aumento da espessura das paredes e dilata&#231;&#227;o do ventr&#237;culo esquerdo leves e, o mesmo, em grau moderado, no ventr&#237;culo direito (<xref ref-type="fig" rid="fig02">Figura 2a</xref>). O mioc&#225;rdio como um todo se apresentava enrijecido, &#8220;borrachoso&#8221; e de tonalidade castanho-amarelada, notando-se ainda granulosidades amareladas discretas na superf&#237;cie endoc&#225;rdica do &#225;trio esquerdo ( <xref ref-type="fig" rid="fig02">b</xref>, <xref ref-type="fig" rid="fig02">c</xref> e <xref ref-type="fig" rid="fig02">d</xref>). Foram constatados tamb&#233;m sinais de insufici&#234;ncia card&#237;aca congestiva, tais como: derrames cavit&#225;rios (hidrot&#243;rax - com 1.560 mL &#224; direita e 1.200 mL &#224; esquerda, e hidroperit&#244;nio - com 960 mL, de l&#237;quido amarelo-citrino), bem como aspecto de congest&#227;o passiva cr&#244;nica em pulm&#245;es e f&#237;gado. </p>
    <fig id="fig02">
      <graphic xlink:href="1678-4170-abc-93-05-0569-00020-gf02.jpg"/></fig>
    <p>O exame histol&#243;gico do mioc&#225;rdio revelou abundante dep&#243;sito de material amorfo e r&#243;seo dentro do sarcolema de miocardi&#243;citos e no interst&#237;cio em torno desses, que foi positivo pela colora&#231;&#227;o de vermelho-Congo (<xref ref-type="fig" rid="fig03">Figura 3</xref>), com refring&#234;ncia em tonalidade verde-garrafa ou verde-ma&#231;&#227; pela luz polarizada, consistente com dep&#243;sito amiloide (<xref ref-type="fig" rid="fig04">Figura 4</xref>). A deposi&#231;&#227;o amiloide foi observada, ainda, em vasos e musculatura lisa de m&#250;ltiplos &#243;rg&#227;os, tais como: pulm&#245;es (em septos alveolares e vasos); ba&#231;o (em regi&#245;es periarteriolares e junto a fol&#237;culos); rins (em vasos); intestinos (musculatura lisa da parede e vasos); tireoide (em vasos). </p>
    <fig id="fig03">
      <graphic xlink:href="1678-4170-abc-93-05-0569-00020-gf03.jpg"/></fig>
    <fig id="fig04">
      <graphic xlink:href="1678-4170-abc-93-05-0569-00020-gf04.jpg"/></fig>
    <p>A medula &#243;ssea foi investigada pela possibilidade de discrasia plasmocit&#225;ria e constatou-se infiltra&#231;&#227;o acentuada por plasm&#243;citos, moderadamente a bem diferenciados, perfazendo cerca de 80% dos elementos celulares. O estudo imuno-histoqu&#237;mico com anticorpos para cadeias leves kappa e lambda, revelou o perfil monoclonal lambda da infiltra&#231;&#227;o plasmocit&#225;ria presente na medula &#243;ssea (<xref ref-type="fig" rid="fig05">Figura 5</xref>). Foram observados ainda &#234;mbolos de c&#233;lulas plasmocit&#225;rias em vasos dos pulm&#245;es, que poderiam corresponder a leucemiza&#231;&#227;o. Al&#233;m disso, os rins apresentavam as altera&#231;&#245;es descritas em casos de mieloma m&#250;ltiplo, com superf&#237;cie renal difusa e finamente granulosa e, na histologia, numerosos cilindros hialinos ou finamente granulosos, em t&#250;bulos da medular renal. A estes achados estavam associadas ainda altera&#231;&#245;es de exames laboratoriais (anemia normoc&#237;tica normocr&#244;mica, aumento de creatinina e protein&#250;ria).</p>
    <fig id="fig05">
      <graphic xlink:href="1678-4170-abc-93-05-0569-00020-gf05.jpg"/></fig>
    <p>Outros achados de menor import&#226;ncia para o quadro cl&#237;nico foram um hemangioma hep&#225;tico, com 1,5 cm e ateromasia discret&#237;ssima da aorta.</p>
    <p>Como causa terminal do &#243;bito foi observado tromboembolismo pulmonar direito, com trombo&#234;mbolo em art&#233;ria lobar, com extensa &#225;rea de hemorragia em lobo inferior direito, e consequente choque cardiog&#234;nico, com edema cerebral (1240g), com leve achatamento de giros na convexidade e hernia&#231;&#227;o de am&#237;gdalas cerebelares. </p>
    <p>
      <bold>Dra. Jussara Bianchi Castelli</bold>
    </p>
    <p>
      <bold> Diagn&#243;sticos anatomopatol&#243;gicos</bold>
    </p>
    <p>Neoplasia maligna de c&#233;lulas plasmocit&#225;rias lambda na medula &#243;ssea, associada a demais altera&#231;&#245;es anatomopatol&#243;gicas e laboratoriais, consistente com o diagn&#243;stico de mieloma m&#250;ltiplo, incluindo amiloidose prim&#225;ria ou amiloidose sist&#234;mica AL, com dep&#243;sitos em cora&#231;&#227;o (acentuado), pulm&#245;es, ba&#231;o, rins, trato digest&#243;rio e tireoide; tromboembolismo pulmonar &#224; direita; choque cardiog&#234;nico; hemangioma hep&#225;tico; aterosclerose leve da aorta. </p>
    <p>
      <bold>Dra. Jussara Bianchi Castelli</bold>
    </p>
    <p>
      <bold>Coment&#225;rios </bold>
    </p>
    <p>A amiloidose &#233; um processo associado a m&#250;ltiplas doen&#231;as que t&#234;m em comum a deposi&#231;&#227;o de prote&#237;nas de apar&#234;ncia semelhante (natureza f&#237;sica semelhante), com vari&#225;vel rompimento estrutural e funcional do &#243;rg&#227;o comprometido pelo dep&#243;sito <sup>30,31</sup>. Na microscopia eletr&#244;nica, cristalografia de raios X e espectroscopia infravermelha, a estrutura fibrilar &#233; id&#234;ntica em todos os tipos de amiloidose, sendo o amiloide constitu&#237;do de prote&#237;nas fibrilares (95%) e de glicoprote&#237;nas (5%). Difere, no entanto, quanto &#224; sua natureza qu&#237;mica, que inclui 15 formas bioqu&#237;micas distintas, sendo tr&#234;s as mais comuns: AL, AA e A&#946;<sup>31</sup>.</p>
    <p>A forma AL (amiloide de cadeia leve), a mais comum de amiloidose, &#233; constitu&#237;da por fragmentos de cadeias leves de imunoglobulinas. Ocorre entre 5% e 15% dos pacientes com mieloma m&#250;ltiplo e tamb&#233;m em pacientes sem mieloma: estes &#250;ltimos teriam aumento no n&#250;mero de plasm&#243;citos na medula &#243;ssea (discrasia plasmocit&#225;ria), que s&#227;o as chamadas gamopatias monoclonais, disproteinemias ou paraproteinemias. Portanto, a amiloidose AL pode estar presente em condi&#231;&#245;es malignas (como no presente caso), benignas ou pr&#233;-malignas. Nesse tipo, o linf&#243;cito B maduro em prolifera&#231;&#227;o monoclonal produz um &#250;nico tipo de imunoglobulina, que se deposita. Na amiloidose prim&#225;ria, cerca de 80% dos pacientes t&#234;m somente a imunoglobulina monoclonal, a maioria lambda, sendo modesta a plasmocitose medular, e 20%, mieloma m&#250;ltiplo<sup>30,31</sup>.</p>
    <p>A forma AA est&#225; relacionada a um derivado da prote&#237;na plasm&#225;tica SAA (do ingl&#234;s &#8220;serum amyloid associated protein&#8221;), produzida no f&#237;gado para auxiliar a fagocitose por macr&#243;fagos. Ocorre na vig&#234;ncia de doen&#231;as inflamat&#243;rias cr&#244;nicas, tais como lepra lepromatosa, tuberculose, osteomielite, bronquiectasias, e artrite reumatoide, com dura&#231;&#227;o de anos<sup>31</sup>.</p>
    <p>A forma A&#946; &#233; encontrada na les&#227;o cerebral (placas) e em vasos da doen&#231;a de Alzheimer. Al&#233;m disso, h&#225; tamb&#233;m a ATTR (derivada da transtiretina ou pr&#233;-albumina), prote&#237;na plasm&#225;tica que transporta tiroxina e retinol (vitamina A), que est&#225; presente em grupos de dist&#250;rbios geneticamente determinados (familiar) e no dep&#243;sito encontrado no cora&#231;&#227;o de idosos (amiloidose sist&#234;mica senil), entre outras formas que n&#227;o ser&#227;o aqui detalhadas<sup>31</sup>.</p>
    <p>Quanto ao diagn&#243;stico da amiloidose, esse depende da identifica&#231;&#227;o morfol&#243;gica do amiloide em amostras de tecido apropriadas e observadas na microscopia &#243;ptica<sup>31,32</sup>. Na suspeita cl&#237;nica, o primeiro passo seria a demonstra&#231;&#227;o do dep&#243;sito amiloide e tem sido utilizada a bi&#243;psia de gordura abdominal<sup>33,34</sup>, que &#233; positiva em 85% dos casos de amiloidose AL<sup>33</sup>. Uma vez detectado o dep&#243;sito suspeito, que se caracteriza por material amorfo e eosinof&#237;lico claro no tecido, esse deve ser analisado com a colora&#231;&#227;o de vermelho-Congo, idealmente em cortes de 10 &#181;m de espessura. Essa colora&#231;&#227;o, se positiva, resultar&#225; em tonalidade vermelha, na luz normal, e verde-ma&#231;&#227; ou verde-garrafa na luz polarizada. A partir da&#237;, a investiga&#231;&#227;o do tipo de amiloide deve prosseguir conforme algoritmo j&#225; estabelecido<sup>33</sup>. Se n&#227;o h&#225; hist&#243;ria familiar, pensa-se primeiramente no tipo AL que abarca a maioria dos casos. Assim, a investiga&#231;&#227;o segue com a procura de discrasia plasmocit&#225;ria atrav&#233;s da pesquisa proteica por imunofixa&#231;&#227;o do sangue e urina, al&#233;m de bi&#243;psia de medula &#243;ssea. A imunofixa&#231;&#227;o, que substitui a t&#233;cnica de imunoeletroforese por ser mais sens&#237;vel e r&#225;pida, combina as t&#233;cnicas de eletroforese e imunoprecipita&#231;&#227;o, que pela intera&#231;&#227;o ant&#237;geno-anticorpo aumenta a capacidade de identificar as imunoglobulinas espec&#237;ficas mediante o uso de anticorpos espec&#237;ficos. A bi&#243;psia de medula &#243;ssea deve ser estudada com o emprego de imuno-histoqu&#237;mica para as cadeias leves kappa e lambda. Se as pesquisas forem negativas, a investiga&#231;&#227;o deve seguir em dire&#231;&#227;o &#224;s demais formas<sup>33</sup>. A determina&#231;&#227;o do tipo de amiloide &#233; necess&#225;ria, pois o tratamento, al&#233;m de suporte de acordo com o &#243;rg&#227;o afetado, deve ser dirigido para a causa b&#225;sica para redu&#231;&#227;o ou parada da deposi&#231;&#227;o amiloide<sup>33-,35</sup>, sendo ainda a inibi&#231;&#227;o da forma&#231;&#227;o das fibrilas amiloides e drogas antiamiloide com a&#231;&#227;o proteol&#237;tica, dois outros alvos de tratamento ainda em estudo<sup>34,35</sup>.</p>
    <p>O progn&#243;stico &#233; reservado na amiloidose generalizada do tipo AL, com sobrevida de 1 a 2 anos<sup>33</sup>. H&#225; melhora da evolu&#231;&#227;o com a utiliza&#231;&#227;o combinada do transplante aut&#243;logo de medula &#243;ssea e a quimioterapia<sup>4,35</sup>. Na sist&#234;mica reativa (AA), o progn&#243;stico &#233; dependente do dist&#250;rbio subjacente<sup>33</sup>. </p>
    <p>
      <bold>Dra. Jussara Bianchi Castelli</bold>
    </p>
    <p>
      <fn id="end" fn-type="corresp">
        <p>Correspond&#234;ncia:</p>
        <p> Vera D. Aiello </p>
        <p> InCor </p>
        <p> Av. Dr. En&#233;as de Carvalho Aguiar, 44 </p>
        <p> 05403-000 &#150; S&#227;o Paulo, SP </p>
        <p> E-mail: </p>
        <p>
          <email xlink:href="anpvera@incor.usp.br">anpvera@incor.usp.br</email>
        </p>
      </fn>
    </p>
    <p><bold>Editor da Se&#231;&#227;o:</bold> Alfredo Jos&#233; Mansur (<email xlink:href="ajmansur@incor.usp.br">ajmansur@incor.usp.br</email>) </p>
    <p><bold>Editores Associados:</bold> Desid&#233;rio Favarato (<email xlink:href="dclfavarato@incor.usp.br">dclfavarato@incor.usp.br</email>) </p>
    <p> Vera Demarchi Aiello (<email xlink:href="anpvera@incor.usp.br">anpvera@incor.usp.br</email>)</p>
  </body>
  <back>
    <ref-list>
      <ref id="B1">
        <mixed-citation>1. Hunt SA, Abraham WT, Chin MH, Feldman AM,    Franas GS, Ganiats TG, et al. ACC/AHA 2005 Guideline Update for the Diagnosis    and Management of Chronic Heart Failure in the Adult: a report of the American    College of Cardiology/American Heart Association Task Force on Practice Guidelines    (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management    of Heart Failure): developed in collaboration with the American College of Chest    Physicians and the International Society for Heart and Lung Transplantation:    endorsed by the Heart Rhythm Society. Circulation. 2005; 112: 154-235.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society</article-title>
          <source>Circulation</source>
          <date>
            <year>2005</year>
          </date>
          <fpage>154</fpage>
          <lpage>235</lpage>
          <volume>112</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Hunt</surname>
              <given-names>SA</given-names>
            </name>
            <name>
              <surname>Abraham</surname>
              <given-names>WT</given-names>
            </name>
            <name>
              <surname>Chin</surname>
              <given-names>MH</given-names>
            </name>
            <name>
              <surname>Feldman</surname>
              <given-names>AM</given-names>
            </name>
            <name>
              <surname>Franas</surname>
              <given-names>GS</given-names>
            </name>
            <name>
              <surname>Ganiats</surname>
              <given-names>TG</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B2">
        <mixed-citation>2. Chizner MA. The diagnosis of heart disease    by clinical assessment alone. Curr Probl Cardiol. 2001; 26: 285-379.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>The diagnosis of heart disease by clinical assessment alone</article-title>
          <source>Curr Probl Cardiol</source>
          <date>
            <year>2001</year>
          </date>
          <fpage>285</fpage>
          <lpage>379</lpage>
          <volume>26</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Chizner</surname>
              <given-names>MA</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B3">
        <mixed-citation>3. Simons M, Isner JM. Assessment of relative    sensitivities of noninvasive tests for cardiac amyloidosis in documented cardiac    amyloidosis. Am J Cardiol. 1992; 69: 425-7.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Assessment of relative sensitivities of noninvasive tests for cardiac amyloidosis in documented cardiac amyloidosis</article-title>
          <source>Am J Cardiol</source>
          <date>
            <year>1992</year>
          </date>
          <fpage>425</fpage>
          <lpage>7</lpage>
          <volume>69</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Simons</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Isner</surname>
              <given-names>JM</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B4">
        <mixed-citation>4. Rahman JE, Helou EF, Gelzer-Bell R, Thompson    RE, Kuo C, Rodriguez ER, et al. Noninvasive diagnosis of biopsy-proven cardiac    amyloidosis. J Am Coll Cardiol. 2004; 43: 410-5.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Noninvasive diagnosis of biopsy-proven cardiac amyloidosis</article-title>
          <source>J Am Coll Cardiol</source>
          <date>
            <year>2004</year>
          </date>
          <fpage>410</fpage>
          <lpage>5</lpage>
          <volume>43</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Rahman</surname>
              <given-names>JE</given-names>
            </name>
            <name>
              <surname>Helou</surname>
              <given-names>EF</given-names>
            </name>
            <name>
              <surname>Gelzer-Bell</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Thompson</surname>
              <given-names>RE</given-names>
            </name>
            <name>
              <surname>Kuo</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Rodriguez</surname>
              <given-names>ER</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B5">
        <mixed-citation>5. Murtagh B, Hammill SC, Gertz MA, Kyle RA,    Tajik AJ, Grogan M. Electrocardiographic findings in primary systemic amyloidosis    and biopsy-proven cardiac involvement. Am J Cardiol. 2005; 95: 535-7.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Electrocardiographic findings in primary systemic amyloidosis and biopsy-proven cardiac involvement</article-title>
          <source>Am J Cardiol</source>
          <date>
            <year>2005</year>
          </date>
          <fpage>535</fpage>
          <lpage>7</lpage>
          <volume>95</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Murtagh</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Hammill</surname>
              <given-names>SC</given-names>
            </name>
            <name>
              <surname>Gertz</surname>
              <given-names>MA</given-names>
            </name>
            <name>
              <surname>Kyle</surname>
              <given-names>RA</given-names>
            </name>
            <name>
              <surname>Tajik</surname>
              <given-names>AJ</given-names>
            </name>
            <name>
              <surname>Grogan</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B6">
        <mixed-citation>6.Patel AR, Dubrey SW, Mendes LA, Skinner A,    Cupples RH, Falk RH, et al. Right ventricular dilation in primary amyloidosis:    an independent predictor of survival. Am J Cardiol. 1997; 80: 486-92.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Right ventricular dilation in primary amyloidosis: an independent predictor of survival</article-title>
          <source>Am J Cardiol</source>
          <date>
            <year>1997</year>
          </date>
          <fpage>486</fpage>
          <lpage>92</lpage>
          <volume>80</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Patel</surname>
              <given-names>AR</given-names>
            </name>
            <name>
              <surname>Dubrey</surname>
              <given-names>SW</given-names>
            </name>
            <name>
              <surname>Mendes</surname>
              <given-names>LA</given-names>
            </name>
            <name>
              <surname>Skinner</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Cupples</surname>
              <given-names>RH</given-names>
            </name>
            <name>
              <surname>Falk</surname>
              <given-names>RH</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B7">
        <mixed-citation>7. McCarthy RE 3rd, Kasper EK. A review of the    amyloidoses that infiltrate the heart. Clin Cardiol. 1998; 21: 547-52.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>A review of the amyloidoses that infiltrate the heart</article-title>
          <source>Clin Cardiol</source>
          <date>
            <year>1998</year>
          </date>
          <fpage>547</fpage>
          <lpage>52</lpage>
          <volume>21</volume>
          <person-group person-group-type="author">
            <name>
              <surname>McCarthy</surname>
              <given-names>RE 3rd</given-names>
            </name>
            <name>
              <surname>Kasper</surname>
              <given-names>EK</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B8">
        <mixed-citation>8. Pellikka PA, Holmes DR Jr, Edwards WD, Nishimura    RA, Tajik AJ, Kyle RA. Endomyocardial biopsy in 30 patients with primary amyloidosis    and suspected cardiac involvement. Arch Intern Med. 1988; 148: 662-6.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Endomyocardial biopsy in 30 patients with primary amyloidosis and suspected cardiac involvement</article-title>
          <source>Arch Intern Med</source>
          <date>
            <year>1988</year>
          </date>
          <fpage>662</fpage>
          <lpage>6</lpage>
          <volume>148</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Pellikka</surname>
              <given-names>PA</given-names>
            </name>
            <name>
              <surname>Holmes</surname>
              <given-names>DR Jr</given-names>
            </name>
            <name>
              <surname>Edwards</surname>
              <given-names>WD</given-names>
            </name>
            <name>
              <surname>Nishimura</surname>
              <given-names>RA</given-names>
            </name>
            <name>
              <surname>Tajik</surname>
              <given-names>AJ</given-names>
            </name>
            <name>
              <surname>Kyle</surname>
              <given-names>RA</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B9">
        <mixed-citation>9. Barreto ACP, Dauar D. Cardiomiopatia restritiva.    Rev Bras Med. 1986; 5: 29-31.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Cardiomiopatia restritiva</article-title>
          <source>Rev Bras Med</source>
          <date>
            <year>1986</year>
          </date>
          <fpage>29</fpage>
          <lpage>31</lpage>
          <volume>5</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Barreto</surname>
              <given-names>ACP</given-names>
            </name>
            <name>
              <surname>Dauar</surname>
              <given-names>D</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B10">
        <mixed-citation>10. Newman LS, Rose CS, Maier LA. Sarcoidosis.    N Engl J Med. 1997; 336: 1224-34.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Sarcoidosis</article-title>
          <source>N Engl J Med</source>
          <date>
            <year>1997</year>
          </date>
          <fpage>1224</fpage>
          <lpage>34</lpage>
          <volume>336</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Newman</surname>
              <given-names>LS</given-names>
            </name>
            <name>
              <surname>Rose</surname>
              <given-names>CS</given-names>
            </name>
            <name>
              <surname>Maier</surname>
              <given-names>LA</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B11">
        <mixed-citation>11. Smedema JP, Snoep G, van Kroonenburgh MP,    van Geuns RJ, Dassen WR, Gorgels AP, et al. Cardiac involvement in patients    with pulmonary sarcoidosis assessed at two university medical centers in the    Netherlands. Chest. 2005; 128: 30-5.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Cardiac involvement in patients with pulmonary sarcoidosis assessed at two university medical centers in the Netherlands</article-title>
          <source>Chest</source>
          <date>
            <year>2005</year>
          </date>
          <fpage>30</fpage>
          <lpage>5</lpage>
          <volume>128</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Smedema</surname>
              <given-names>JP</given-names>
            </name>
            <name>
              <surname>Snoep</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>van Kroonenburgh</surname>
              <given-names>MP</given-names>
            </name>
            <name>
              <surname>van Geuns</surname>
              <given-names>RJ</given-names>
            </name>
            <name>
              <surname>Dassen</surname>
              <given-names>WR</given-names>
            </name>
            <name>
              <surname>Gorgels</surname>
              <given-names>AP</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B12">
        <mixed-citation>12. Chapelon-Abric C, de Zuttere D, Duhaut P,    Veyssier P, Wechsler B, Huong DL, et al. Cardiac sarcoidosis: a retrospective    study of 41 cases. Medicine (Baltimore). 2004; 83: 315-34.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Cardiac sarcoidosis: a retrospective study of 41 cases</article-title>
          <source>Medicine (Baltimore)</source>
          <date>
            <year>2004</year>
          </date>
          <fpage>315</fpage>
          <lpage>34</lpage>
          <volume>83</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Chapelon-Abric</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>de Zuttere</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Duhaut</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Veyssier</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Wechsler</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Huong</surname>
              <given-names>DL</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B13">
        <mixed-citation>13. Iwai K, Sekiguti M, Hosoda Y, DeRemee RA,    Tazelaar HD, Sharma OP, et al. Racial difference in cardiac sarcoidosis incidence    observed at autopsy. Sarcoidosis. 1994; 11: 26-31.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Racial difference in cardiac sarcoidosis incidence observed at autopsy</article-title>
          <source>Sarcoidosis</source>
          <date>
            <year>1994</year>
          </date>
          <fpage>26</fpage>
          <lpage>31</lpage>
          <volume>11</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Iwai</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Sekiguti</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Hosoda</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>DeRemee</surname>
              <given-names>RA</given-names>
            </name>
            <name>
              <surname>Tazelaar</surname>
              <given-names>HD</given-names>
            </name>
            <name>
              <surname>Sharma</surname>
              <given-names>OP</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B14">
        <mixed-citation>14. Thomsen TK, Eriksson T. Myocardial sarcoidosis    in forensic medicine. Am J Forensic Med Pathol. 1999; 20: 52-6.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Myocardial sarcoidosis in forensic medicine</article-title>
          <source>Am J Forensic Med Pathol</source>
          <date>
            <year>1999</year>
          </date>
          <fpage>52</fpage>
          <lpage>6</lpage>
          <volume>20</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Thomsen</surname>
              <given-names>TK</given-names>
            </name>
            <name>
              <surname>Eriksson</surname>
              <given-names>T</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B15">
        <mixed-citation>15. Winterbauer RH, Lammert J, Selland M, Wu    R, Corley D, Springmeyer SC. Bronchoalveolar lavage cell populations in the    diagnosis of sarcoidosis. Chest. 1993; 104: 352-61.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Bronchoalveolar lavage cell populations in the diagnosis of sarcoidosis</article-title>
          <source>Chest</source>
          <date>
            <year>1993</year>
          </date>
          <fpage>352</fpage>
          <lpage>61</lpage>
          <volume>104</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Winterbauer</surname>
              <given-names>RH</given-names>
            </name>
            <name>
              <surname>Lammert</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Selland</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Wu</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Corley</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Springmeyer</surname>
              <given-names>SC</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B16">
        <mixed-citation>16. Uemura A, Morimoto S, Hiramitsu S, Kato Y,    Ito T, Hishida H. Histologic diagnostic rate of cardiac sarcoidosis: evaluation    of endomyocardial biopsies. Am Heart J. 1999; 138: 299-302.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Histologic diagnostic rate of cardiac sarcoidosis: evaluation of endomyocardial biopsies</article-title>
          <source>Am Heart J</source>
          <date>
            <year>1999</year>
          </date>
          <fpage>299</fpage>
          <lpage>302</lpage>
          <volume>138</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Uemura</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Morimoto</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Hiramitsu</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Kato</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Ito</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Hishida</surname>
              <given-names>H</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B17">
        <mixed-citation>17. Fahy GJ, Marwick T, McCreery CJ, Quigley    PJ, Maurer BJ. Doppler echocardiographic detection of left ventricular diastolic    dysfunction in patients with pulmonary sarcoidosis. Chest. 1996; 109: 62-6.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Doppler echocardiographic detection of left ventricular diastolic dysfunction in patients with pulmonary sarcoidosis</article-title>
          <source>Chest</source>
          <date>
            <year>1996</year>
          </date>
          <fpage>62</fpage>
          <lpage>6</lpage>
          <volume>109</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Fahy</surname>
              <given-names>GJ</given-names>
            </name>
            <name>
              <surname>Marwick</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>McCreery</surname>
              <given-names>CJ</given-names>
            </name>
            <name>
              <surname>Quigley</surname>
              <given-names>PJ</given-names>
            </name>
            <name>
              <surname>Maurer</surname>
              <given-names>BJ</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B18">
        <mixed-citation>18. Edwards CQ, Kushner JP. Screening for hemochromatosis.    N Engl J Med. 1993; 328: 1616-20.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Screening for hemochromatosis</article-title>
          <source>N Engl J Med</source>
          <date>
            <year>1993</year>
          </date>
          <fpage>1616</fpage>
          <lpage>20</lpage>
          <volume>328</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Edwards</surname>
              <given-names>CQ</given-names>
            </name>
            <name>
              <surname>Kushner</surname>
              <given-names>JP</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B19">
        <mixed-citation>19. Edwards CQ, Griffen LM, Goldgar D, Drummond    C, Skolnick MH, Kushner JP. Prevalence of hemochromatosis among 11,065 presumably    healthy blood donors. N Engl J Med. 1988; 318: 1355-62.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Prevalence of hemochromatosis among 11,065 presumably healthy blood donors</article-title>
          <source>N Engl J Med</source>
          <date>
            <year>1988</year>
          </date>
          <fpage>1355</fpage>
          <lpage>62</lpage>
          <volume>318</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Edwards</surname>
              <given-names>CQ</given-names>
            </name>
            <name>
              <surname>Griffen</surname>
              <given-names>LM</given-names>
            </name>
            <name>
              <surname>Goldgar</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Drummond</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Skolnick</surname>
              <given-names>MH</given-names>
            </name>
            <name>
              <surname>Kushner</surname>
              <given-names>JP</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B20">
        <mixed-citation>20. Lynch SR, Skikne BS, Cook JD. Food iron absorption    in idiopathic hemochromatosis. Blood. 1989; 74: 2187-93.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Food iron absorption in idiopathic hemochromatosis</article-title>
          <source>Blood</source>
          <date>
            <year>1989</year>
          </date>
          <fpage>2187</fpage>
          <lpage>93</lpage>
          <volume>74</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Lynch</surname>
              <given-names>SR</given-names>
            </name>
            <name>
              <surname>Skikne</surname>
              <given-names>BS</given-names>
            </name>
            <name>
              <surname>Cook</surname>
              <given-names>JD</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B21">
        <mixed-citation>21. Smith LH Jr. Pumping iron. West J Med. 1995;    162: 370-1.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Pumping iron</article-title>
          <source>West J Med</source>
          <date>
            <year>1995</year>
          </date>
          <fpage>370</fpage>
          <lpage>1</lpage>
          <volume>162</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Smith</surname>
              <given-names>LH Jr</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B22">
        <mixed-citation>22. Niederau C, Strohmeyer G, Stremmel W. Epidemiology,    clinical spectrum and prognosis of hemochromatosis. Adv Exp Med Biol. 1994;    356: 293-302.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Epidemiology, clinical spectrum and prognosis of hemochromatosis</article-title>
          <source>Adv Exp Med Biol</source>
          <date>
            <year>1994</year>
          </date>
          <fpage>293</fpage>
          <lpage>302</lpage>
          <volume>356</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Niederau</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Strohmeyer</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Stremmel</surname>
              <given-names>W</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B23">
        <mixed-citation>23. Olson LJ, Edwards WD, McCall JT, Ilstrup    DM, Gersh BJ. Cardiac iron deposition in idiopathic hemochromatosis: histologic    and analytic assessment of 14 hearts from autopsy. J Am Coll Cardiol. 1987;    10: 1239-43.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Cardiac iron deposition in idiopathic hemochromatosis: histologic and analytic assessment of 14 hearts from autopsy</article-title>
          <source>J Am Coll Cardiol</source>
          <date>
            <year>1987</year>
          </date>
          <fpage>1239</fpage>
          <lpage>43</lpage>
          <volume>10</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Olson</surname>
              <given-names>LJ</given-names>
            </name>
            <name>
              <surname>Edwards</surname>
              <given-names>WD</given-names>
            </name>
            <name>
              <surname>McCall</surname>
              <given-names>JT</given-names>
            </name>
            <name>
              <surname>Ilstrup</surname>
              <given-names>DM</given-names>
            </name>
            <name>
              <surname>Gersh</surname>
              <given-names>BJ</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B24">
        <mixed-citation>24. Desnick RJ, Brady R, Barranger J, Collins    AJ, Germain DP, Goldman M, et al. Fabry disease, an under-recognized multisystemic    disorder: expert recommendations for diagnosis, management, and enzyme replacement    therapy. Ann Intern Med. 2003; 138 (4): 338-46.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Fabry disease, an under-recognized multisystemic disorder: expert recommendations for diagnosis, management, and enzyme replacement therapy</article-title>
          <source>Ann Intern Med</source>
          <date>
            <year>2003</year>
          </date>
          <fpage>338</fpage>
          <lpage>46</lpage>
          <issue>4</issue>
          <volume>138</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Desnick</surname>
              <given-names>RJ</given-names>
            </name>
            <name>
              <surname>Brady</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Barranger</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Collins</surname>
              <given-names>AJ</given-names>
            </name>
            <name>
              <surname>Germain</surname>
              <given-names>DP</given-names>
            </name>
            <name>
              <surname>Goldman</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B25">
        <mixed-citation>25. Sachdev B, Takenaka T, Teraguchi H, Tei C,    Lee P, McKenna WJ, et al. Prevalence of Anderson-Fabry disease in male patients    with late onset hypertrophic cardiomyopathy. Circulation. 2002; 105 (12): 1407-11.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Prevalence of Anderson-Fabry disease in male patients with late onset hypertrophic cardiomyopathy</article-title>
          <source>Circulation</source>
          <date>
            <year>2002</year>
          </date>
          <fpage>1407</fpage>
          <lpage>11</lpage>
          <issue>12</issue>
          <volume>105</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Sachdev</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Takenaka</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Teraguchi</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Tei</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Lee</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>McKenna</surname>
              <given-names>WJ</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B26">
        <mixed-citation>26. Nakao S, Takenaka T, Maeda M, Kodama C, Tanaka    A, Takahara M, et al. An atypical variant of Fabry's disease in men with    left ventricular hypertrophy. N Engl J Med. 1995; 333 (5): 288-93.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>An atypical variant of Fabry's disease in men with left ventricular hypertrophy</article-title>
          <source>N Engl J Med</source>
          <date>
            <year>1995</year>
          </date>
          <fpage>288</fpage>
          <lpage>93</lpage>
          <issue>5</issue>
          <volume>333</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Nakao</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Takenaka</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Maeda</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Kodama</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Tanaka</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Takahara</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B27">
        <mixed-citation>27. Pieroni M, Chimenti C, De Cobelli F, Morgante    E, Del Maschio A, Gaudio C, et al. Fabry's disease cardiomyopathy: echocardiographic    detection of endomyocardial glycosphingolipid compartmentalization. J Am Coll    Cardiol. 2006; 47 (8): 1663-71.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Fabry's disease cardiomyopathy: echocardiographic detection of endomyocardial glycosphingolipid compartmentalization</article-title>
          <source>J Am Coll Cardiol</source>
          <date>
            <year>2006</year>
          </date>
          <fpage>1663</fpage>
          <lpage>71</lpage>
          <issue>8</issue>
          <volume>47</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Pieroni</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Chimenti</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>De Cobelli</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Morgante</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Del Maschio</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Gaudio</surname>
              <given-names>C</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B28">
        <mixed-citation>28. Gersh BJ, McKenna W, Yeon SB. Cardiac manifestations    of Fabry disease and screening in patients with left ventricular hypertrophy:    Up toDate. (on line). [Acessed on 2009 Oct 9]. Available from: <ext-link ext-link-type="uri" xlink:href="http://www.uptodate.com/patients/content/topic.do?topickey=~exe181lok2">http://www.uptodate.com/patients/content/topic.do?topickey=~exe181lok2</ext-link>.</mixed-citation>
        <element-citation publication-type="book">
          <source>Cardiac manifestations of Fabry disease and screening in patients with left ventricular hypertrophy</source>
          <person-group person-group-type="author">
            <name>
              <surname>Gersh</surname>
              <given-names>BJ</given-names>
            </name>
            <name>
              <surname>McKenna</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Yeon</surname>
              <given-names>SB</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B29">
        <mixed-citation>29. Hassan WM, Fawzy ME, Al Helaly S, Hegazy    H, Malik S. Pitfalls in diagnosis and clinical, echocardiographic, and hemodynamic    findings in endomyocardial fibrosis: a 25-year experience. Chest. 2005; 128:    3985-92.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Pitfalls in diagnosis and clinical, echocardiographic, and hemodynamic findings in endomyocardial fibrosis: a 25-year experience</article-title>
          <source>Chest</source>
          <date>
            <year>2005</year>
          </date>
          <fpage>3985</fpage>
          <lpage>92</lpage>
          <volume>128</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Hassan</surname>
              <given-names>WM</given-names>
            </name>
            <name>
              <surname>Fawzy</surname>
              <given-names>ME</given-names>
            </name>
            <name>
              <surname>Al Helaly</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Hegazy</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Malik</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B30">
        <mixed-citation>30. Shaheen SP, Talwalkar SS, Medeiros LJ. Multiple    myeloma and immunosecretory disorders: an update. Adv Anat Pathol. 2008; 15:    196-210.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Multiple myeloma and immunosecretory disorders</article-title>
          <source>Adv Anat Pathol</source>
          <date>
            <year>2008</year>
          </date>
          <fpage>196</fpage>
          <lpage>210</lpage>
          <volume>15</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Shaheen</surname>
              <given-names>SP</given-names>
            </name>
            <name>
              <surname>Talwalkar</surname>
              <given-names>SS</given-names>
            </name>
            <name>
              <surname>Medeiros</surname>
              <given-names>LJ</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B31">
        <mixed-citation>31. Robbins SL, Cotran RS, Kumar V. Patologia    estrutural e funcional. 6a ed. Rio de Janeiro: Guanabara Koogan SA; 2000. p.    224-9.</mixed-citation>
        <element-citation publication-type="book">
          <source>Patologia estrutural e funcional</source>
          <date>
            <year>2000</year>
          </date>
          <fpage>224</fpage>
          <lpage>9</lpage>
          <person-group person-group-type="author">
            <name>
              <surname>Robbins</surname>
              <given-names>SL</given-names>
            </name>
            <name>
              <surname>Cotran</surname>
              <given-names>RS</given-names>
            </name>
            <name>
              <surname>Kumar</surname>
              <given-names>V</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B32">
        <mixed-citation>32. Kyle RA, Rajkumar SV. Criteria for diagnosis,    staging, risk stratification and response assessment of multiple myeloma. Leukemia.    2009; 23: 3-9.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma</article-title>
          <source>Leukemia</source>
          <date>
            <year>2009</year>
          </date>
          <fpage>3</fpage>
          <lpage>9</lpage>
          <volume>23</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Kyle</surname>
              <given-names>RA</given-names>
            </name>
            <name>
              <surname>Rajkumar</surname>
              <given-names>SV</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B33">
        <mixed-citation>33. Falk RH, Comenzo RL, Skinner M. The systemic    amyloidoses. N Engl J Med. 1997; 337: 898-909.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>The systemic amyloidoses</article-title>
          <source>N Engl J Med</source>
          <date>
            <year>1997</year>
          </date>
          <fpage>898</fpage>
          <lpage>909</lpage>
          <volume>337</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Falk</surname>
              <given-names>RH</given-names>
            </name>
            <name>
              <surname>Comenzo</surname>
              <given-names>RL</given-names>
            </name>
            <name>
              <surname>Skinner</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B34">
        <mixed-citation>34. Dember LM. Emerging treatment approaches    for the systemic amyloidoses. Kidney Int. 2005; 68: 1377-90.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Emerging treatment approaches for the systemic amyloidoses</article-title>
          <source>Kidney Int</source>
          <date>
            <year>2005</year>
          </date>
          <fpage>1377</fpage>
          <lpage>90</lpage>
          <volume>68</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Dember</surname>
              <given-names>LM</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B35">
        <mixed-citation>35. Wechalekar AD, Hawkins PN, Gillmore JD. Perspectives    in treatment of AL amyloidosis. Br J Haematol. 2008; 140: 365-77.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Perspectives in treatment of AL amyloidosis</article-title>
          <source>Br J Haematol</source>
          <date>
            <year>2008</year>
          </date>
          <fpage>365</fpage>
          <lpage>77</lpage>
          <volume>140</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Wechalekar</surname>
              <given-names>AD</given-names>
            </name>
            <name>
              <surname>Hawkins</surname>
              <given-names>PN</given-names>
            </name>
            <name>
              <surname>Gillmore</surname>
              <given-names>JD</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
    </ref-list>
  </back>
  <sub-article article-type="translation" id="TRen" xml:lang="en">
    <front-stub>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Anatomopathological Session</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title xml:lang="en">Case 5: 50-year-old woman with restrictive cardiomyopathy, renal failure and proteinuria</article-title>
      </title-group>
      <kwd-group xml:lang="en">
        <kwd>Amyloidosis</kwd>
        <kwd>Cardiomyopathy</kwd>
        <kwd>Shock</kwd>
        <kwd>Pulmonary Embolism</kwd>
      </kwd-group>
    </front-stub>
    <body>
      <p>
        <bold>ANATOMOPATHOLOGICAL SESSION</bold>
      </p>
      <p><undefined id="txt-body2"/>Case 5 50-year-old woman with restrictive cardiomyopathy, renal failure and proteinuria</p>
      <p>
        <bold>Odilson Marcos Silvestre; Henrique Barbosa Ribeiro; Leonardo Jorge C. de Paula; S&#233;rgio Ricardo V. Mac&#234;do; Jussara Bianchi Castelli</bold>
      </p>
      <p> Instituto do Cora&#231;&#227;o (InCor) HC-FMUSP, S&#227;o Paulo, SP - Brazil</p>
      <p>Mailing address</p>
      <p><bold>Key words:</bold> Amyloidosis; Cardiomyopathy, Restrictive; Shock, Cardiogenic; Pulmonary Embolism.</p>
      <p>Woman with 50 years of age, born in Pernambuco, coming from S&#227;o Paulo, sought medical assistance due to dyspnea caused by minor stress.</p>
      <p>Four months ago, the patient presented signs of dyspnea caused by moderate effort, which 2 month ago progressed to minimum effortand orthopnea. The patient also presented edema on lower limbs. She sought medical assistance, was diagnosed with heart failure and was admitted for treatment. The patient knew she had hypothyroidism for years. </p>
      <p>During admission, the patient underwent thoracocentesis to drain pleural effusion. The biochemal analysis of the pleural liquid (6 Dec 2007) revealed lactate dehydrogenase (LDH) (pleural effusion/serum) 104/216 = 0.48; protein (pleural effusion/serum) 2.8/6.2 = 0.45; albumin gradient = 1.5.</p>
      <p>The patient was discharged with prescription of 80 mg of Furosemide, 50 mg of Spironolactone, 75 mg of Captopril, 100 &#181;g of levotiroxin on a daily basis, and 0.25 mg of Digoxin every other day. </p>
      <p>Her dyspnea showed some improvement, however, some days later the dyspnea worsened again upon effort levels below the usual ones. The patient sought medical assistance in this Hospital.</p>
      <p>Physical examination (9 Jan 2008) revealed eupneic patient, with increased jugular venous pressure, heart rate at 100 bpm and blood pressure 90 / 80 mm Hg. Lung examination revealed a decreased vesicular murmur on the right hemithorax middle third and abolition on the lower third of both hemithoraxes. Cardiac semiology revealed 4<sup>th</sup> heart sound, with no murmurs or pericardial friction rub. Her abdomen was painful to percussion in right hyponchondrium region. Her liver was palpated at 10 cm from the right coastal edge; there was edema +++/4+ on lower limbs.</p>
      <p>Chest radiography (9 Jan 2008) revealed a huge bilateral pleural effusion.</p>
      <p>ECG (14 Jan 2008) showed sinus rhythm, cardiac frequency 100 bpm, left atrial overload, indirect right atrial overload signs (Pe&#241;aloza-Tranchesi), low voltage of frontal QRS, little progressive R wave of V<sub>1</sub> to V<sub>4</sub> (<xref ref-type="fig" rid="fig01-body2">Figure 1</xref>).</p>
      <fig id="fig01-body2">
        <graphic xlink:href="1678-4170-abc-93-05-0569-00020-gf01-en.jpg"/></fig>
      <p>Laboratory tests (9 Jan 2008) revealed increased creatinine levels (<xref ref-type="table" rid="tab01-body2">Table 1</xref>).</p>
      <table-wrap id="tab01-body2">
        <graphic xlink:href="1678-4170-abc-93-05-0569-00020-gt01-en.jpg"/></table-wrap>
      <p>Echocardiogram (10 Jan 2008) revealed: aorta 29 mm, left atrium 41 mm, right ventricle diastolic diameter 29 mm, left ventricle dimensions (diastole/systole) 38 mm/28 mm, interventricular septum and posterior wall thickness of 13 mm and left ventricle ejection fraction of 52%. Moderate concentric hypertrophy was diagnosed. The patient presented hyper-refringency in the interventricular septum. Systolic ventricular function was depressed due to diffused hipokynesia. Doppler findings were compatible to restrictive pattern with no reversion after Valsalva maneuver. Right ventricle showed discreet hypertrophy and moderate hypokinesia and severe tricuspid valve insufficiency.</p>
      <p>Pleural effusion puncture and drainage were made, as well as heart failure therapy with endovenous furosemide and maintenance of drugs under use.</p>
      <p>The pleural analysis (16 jan 08) revealed LDH ratios (pleural effusion/serum) 120/210 = 0.57; proteins (pleural effusion/serum) 3.6/6.7=0,54; albumin gradient = 1.2, 440 leukocytes/mm&#179;, cholesterol &lt;50 mg/dl, glucose 119 mg/dl</p>
      <p>Abdomen ultrasound (14 Jan 08) revealed hyperecogenic area on hepatic lobe, the ultrasound aspect of which was compatible to haemangioma; besides small volume ascites and bilateral pleural effusion. No other alterations were found.</p>
      <p>Ultrasound of urinary tract (22 Jan 2008) was normal. </p>
      <p>Thorax tomography (17 Jan 2008) revealed a considerable bilateral pleural effusion with atelectasis of lower lobes and posterior segments of upper lobes.</p>
      <p>Despite improvement of dyspnea, right pleural effusion persisted and a progressive worsening of renal functions was observed (<xref ref-type="table" rid="tab01-body2">Tab. 1</xref>). The patient kept a blood pressure at 90 / 60 mm Hg. Therapy with diuretic drugs, Captopril and Digoxin was stopped and Dobutamine was prescribed, along with hemodialysis and the patient was transferred to ICU.</p>
      <p>Skin biopsy (16 Jan 08) was negative for amyloid substance (Congo red).</p>
      <p>On the night of Jan 27, 2008, the patient presented cardiac arrest under pulseless electrical activity. The patient developed hypotension. A new echocardiogram was done to set aside any likelihood of cardiac tamponade, which revealed left ventricle with concentric hypertrophy of discreet degree and septal hyperrefringency, suggesting an infiltration process and impaired systolic function due to diffused hipokynesia. Right ventricle had a pronounced hypokinesia and discreet to moderate pericardial effusion.</p>
      <p>Right thoracic puncture was done and no hemothorax signs were found. Chest radiography after central catheters did not reveal pneumothorax. Around one hour after initial cardiac arrest, new cardiac arrest under pulseless electrical activity, which was irreversible (27 Jan 2008).</p>
      <p>
        <bold>Clinical aspects</bold>
      </p>
      <p>The case described above refers to 50 years old women with hypotireoidism, who presented progressive dyspnea in the past four months despite heart failure therapy.</p>
      <p>Heart failure (HF) constitutes clinical diagnosis through compilation of anamnesis and physical test data<sup>1</sup>. The clinical history of HF is characterized effort dyspnea or tiredness. Findings of orthopnea and paroxysmal nocturnal dyspnea are more specific to diagnose this syndrome. It is important to look for risk factors or previous cardiovascular disease. Physical tests may provide more significant inputs to decompensated HF, since sensitivity is low when it is compensated. Alterations are related to congestion or cardiomegaly, besides findings that may suggest the cardiac disease etiology. This way, peripheral edema, tachycardia at rest, pulmonary rales, jugular vein swelling, hepatojugular reflux, hepatomegaly, deviated cerebrovascular accident and accessory crackles should be sought in the preliminary evaluation. Valvar or pericardial disease may present signs due to the presence of murmurs or pericardial knock, respectively <sup>2</sup>.</p>
      <p>The patient presents history of dyspnea related to effort, progressing over time, culminating with symptoms at minimum effort, orthopnea and need for admission. It is important highlighting that there is no description of cardiovascular risk factors nor previous cardiac disease. Physical tests revealed important findings to diagnose the syndrome and data to start reflecting on the HF etiology. Presence of tachycardia at rest is a common finding, but little specific for the diagnosis. There is no description of cerebrovascular accident, given the undisputable diagnostic importance. Report of jugular vein swelling, hepatomegaly and peripheral edema lead us to think in systemic congestion, that is, right heart failure. We should stress that the presence of jugular vein swelling and decreased pulse pressure (PA 90 x 80 mmHg) determine a worse prognosis. The fourth heart sound crackle suggests myocardial diastolic dysfunction. It is worth reminding that severe hepatomegaly may suggest, besides congestion, hepatic tissue infiltration. Preliminary findings also showed bilateral pleural effusion, mainly on the right, as well as it often happens in HF. The effusion may have contributed to dyspnea. The pleural liquid was analyzed at two moments. Upon admission, the first analysis revealed a transudate, confirming effusion secondary to HF. In the second puncture, the liquid has parameters that suggest exudate, but it is worth reminding that at that time the patent was taking diuretic drugs, which may explain the biochemical change of the liquid.</p>
      <p>Anamnesis and physical data allow diagnosing HF syndrome. However, clinical history shows data that may suggest the etiology, as there are no reports of hypertension, ischemic disease or cardiovascular risk factors. Physical examinations reveal prevailing findings compatible to right HF.</p>
      <p>Upon analysis of complementary tests, chest radiography confirmed the presence of a huge bilateral pleural effusion, but the cardiac area size was not reported.</p>
      <p>Laboratory tests upon admission revealed no consistent alterations in hematological series. Dosing of thyroid hormones revealed that hypothyroidism was compensated. Renal functions was altered since the inception, always with a urea: creatinine ratio &gt; 40, suggesting pre-renal pattern. However, the presence of pathological proteinuria in 24 hour urine suggests renal parenchyma injury. The progressive increase of nitrogenous waste products was possibly related to the use of diuretic drugs during admission.</p>
      <p>Initial electrocardiogram revealed signs of biatrial overload, low frontal QRS voltage, besides R wave little progressing from V1 to V4. Among the conditions progressing with low QRS voltage, we have pericardial effusion, chronic obstructive pulmonary disease and hypothyroidism. Nevertheless, none justify increased cardiac mass detected by transthoracic echocardiogram (TTE). Additionally, no pericardial effusion was found in the TTE, no previous chronic obstructive pulmonary disease, and normal TSH and free T4 clean. On the other hand, the increased myocardial mass as a function of hypertension or hypertrophic cardyomiopathy relates to normal or increase voltage in the electrocardiogram, which was not observed in our case. The presence of hypertrophy in TTE, combined to low electrochardiogram voltage are only found in infiltrative myocardial diseases<sup>3, 4</sup>.</p>
      <p>Amyloidosis in up to 50% of patients may determine to ECG low voltage QRS in limb derivations<sup>4, 5</sup>. Another frequent usual condition related to this disease is the presence of pseudo-infarction pattern. Both in amyloidosis, and in other heart infiltrative diseases, such as hemochromatosis, sarcoidosis or Fabry disease, conduction disorders are common, often associated to advanced blocking, not observed in this case. Additionally, these diseases also develop with paroxysmal or persistent atrial fibrillation, especially amyloidosis and Fabry disease, not observed either.</p>
      <p>Infiltrative cardiomyopathies initially lead to diastolic dysfunction associated to wall hypertrophy, but right ventricle diastolic dysfunction may also occur<sup>6</sup>. In well-developed cases, wall hypertrophy progresses, resulting in restrictive cardiomyopathy, with left ventricular cavity not dilated and small<sup>6</sup>. This pattern, combined with biatrial enlargement are also more frequent in amyloidosis, since in sarcoidosis, especially in hemochromatosis, left ventricular dilation prevails. </p>
      <p>Other important factors determined for differential diagnosis with TTE are the presence of scintillating myocardium, and absence of major valvopathy (only valve thickening), found in amyloidosis. Scintillating myocardium is found little sensitive (26% in a series) and cannot be used to eliminate likelihood of amyloidosis <sup>4</sup>. On the other hand, right ventricular dilation is consider to predict amyloidosis and, associated to increased filling pressures, it justifies tricuspid valve insufficiency often present, as in the case reported in this study. Other infiltrative cardiomyopathies, such as sarcoidosis and Fabry disease may develop with valvopathy, especially mitral and aortic valves<sup>6</sup>.</p>
      <p>Based on the data presented so far, we consider amyloidosis as the main hypothesis. This is a heterogeneous group of hereditary, inflammatory or neoplasm disorders that result in deposits of amyloid fibrils in several organs, such as heart, kidney and nervous system. Amyloid fibrils are considered low molecule weight protein subunits deriving from normal or aberrant serum proteins<sup>7</sup>. Heart attacks are due to myocardial infiltration of these proteins by different pathogenic mechanisms, becoming clinically apparent when extracellular deposits of amyloid bodies changes normal tissue architecture<sup>7</sup>.</p>
      <p>In infiltrative disease, etiology is often confirmed by endomyocardial biopsy. This may happen, for instance, due to Congo red color of amyloid deposits, in amyloidosis; sarcoid granuloma in sarcoidosis; and lamellar bodies in Fabry disease. Nevertheless, endomyocardial biopsy causes impairments and, it often cannot be conducted. Other types of diagnosis should be used. In amyloidosis, this can be done by revealing amyloid deposits in the histopathological examination of biopsies collected from abdominal fat, rectum or kidney tissue. In this patient, subcutaneous cellular tissue was collected, but revealed no amyloid substance. In retrospective studies, the examination of highly sensitive, especially when several samples are used (it gets close to 100% when at least 4 samples are collected)<sup>8</sup>.</p>
      <p>Another revealing test in infiltrative cardiomyopathies is the nuclear magnetic resonance imaging which, in this case, it was not reported, possibly due to the impaired renal function presented, with high likelihood of developing nephrogenic systemic fibrosis.</p>
      <p>Summing up, we have the case of a 50-year-old female patient with no previous cardiovascular disease or comorbidity, which evolved to rapidly progressing dyspnea, getting to minimum stress, associated to orthopnea and systemic congestion (hepatic volume enlargement and lower limb edema). She presented non-specific symptoms, however TTE revealed ventricular hypertrophy, ventricular septal hyperrefringency and Doppler revealed restrictive pattern. These findings are compatible to myocardial infiltration processes. Considering the clinical presentation, electrocardiographic and echocardiographic alterations, presence of proteinuria and hepatomegaly, amyloidosis becomes the main diagnosis hypothesis. However, other infiltrative cardiomyopathies may also be investigated due to the symptoms presented and especially because subcutaneous cellular tissue biopsy was negative.</p>
      <p>Infiltrative cardiomyopathies are classified under restrictive cardiopathies. These are characterized by rigid myocardial walls associated to non-complacency of one or both ventricles. The left ventricle is more commonly involved, leading to improper ventricular filling and consequent increase of final diastolic pressure<sup>9</sup>.</p>
      <p>This group of cardiomyopathies is divided into three distinct classes: </p>
      <p>1) myocardial infiltrations, in which the myocardium is infiltrated by an abnormal substance (such as in amyloidosis, sarcoidosis, hemochromatosis and Fabry disease); </p>
      <p>2) myocardial fibroses, with fibrous extension over the entire myocardial wall (familiar and idiopathic cardiomyopathy); </p>
      <p>3) endomyocardial fibroses, with endocardial and subendocardial attacks (endomyocardial fibrosis (EMF), hypereosinophilic syndrome and metastasis of tumor diseases)<sup>9</sup>.</p>
      <p>Among myocardial infiltrative diseases, cardiac sarcoidosis should be considered a differential diagnosis. </p>
      <p>This is a systemic disease, of unknown etiology, characterized by non-caseous granulomas in any organ, leading to impairment to tissue structures<sup>10</sup>.</p>
      <p>This cardiac disease is generally done after development of symptoms related to dysfunction of other organs (lung, liver, skin and eyes). However, few patients may suffer heart attacks alone, with no other symptoms of this disease<sup>11</sup>. Heart attacks occur in up to 30% of patients, although only 5% of them manifest the disease clinically. The disease is characterized by advanced atrioventricular blocks and abnormal wall thickening<sup>12-14</sup>. Almost all patients present respiratory tract impairments, including hilar lymphadenopathy and interstitial pulmonary infiltrate. Hilar lymphadenopathy attacks 90% of individuals with the disease. Based on the patient's clinical and radiological condition, diagnosis may be suspected, but confirmation should be made from biopsy with demonstration of non-caseous granulomas<sup>15</sup>. </p>
      <p>Besides cardiac dysfunction, the patient presented hepatomegaly with similar hyperecogenic images and hemangiomas. Sarcoidosis rarely causes major hepatic dysfunction, however a slight increase of hepatic enzymes and major increase of canalicular enzymes may occur, which may often lead to portal hypertension symptoms<sup>10</sup>. In the development of the case, considering the diagnosis hypotheses, hepatic or myocardial biopsy could have been conducted, since findings of granulomas close up the diagnosis. Nevertheless, false negative results may occur due because the attack is not homogeneous, mainly in heart diseases<sup>16</sup>. What is against the diagnosis of cardiac sarcoidosis in this patient is the presence of septal hyperrefringency in the TTE, as in sarcoidosis, alterations are not specific and may include ventricular aneurism, cavity dilation and wall thickening<sup>17</sup>.</p>
      <p>Another possible differential diagnosis is the hereditary hemochromatosis. It is characterized as a recessive autosomal disease in which the mutation of gene HEF increases intestinal iron absorption, leading to secondary clinical manifestations upon excessive deposits of iron in the tissues, especially liver, heart, pancreas and hypophysis<sup>18</sup>. The heterozygote form of the disease usually clinically comes out during life. This may be found by measuring transferrin saturation (ratio between the concentration of serum iron and total iron-binding capacity)<sup>19</sup>. The homozygote form may lead to severe manifestations, generally after 40 years of age. Women may present this disease later than men due to menstrual losses before menopause<sup>20,21</sup>. The most frequent manifestations are hepatic alterations, lethargy, hyperpigmentation of skin, diabetes mellitus and electrocardiographic abnormalities<sup>22</sup>. The most common cardiac disorders are ventricular dilation characterized by the development of heart failure and conduction disorders<sup>23</sup>. Ventricular hypertrophy is not characteristic, as well as hyper-refringency found in TTE. In the case above, cardiac dysfunction is not typical and serum iron and ferritin levels were normal, which exclude the diagnosis.</p>
      <p>While investigating the patient, a less probable diagnosis to be reminded is Fabry disease. This disease consists in deposit of glycolipids connected to chromosome X and is caused by a weak activity of liposomal enzyme Alpha-galactosidase A, leading to subsequent accumulation and deposit of globotriaosylceramide in the tissues<sup>24</sup>. An important characteristic is that clinical manifestations generally occur before 10 years of age, including skin lesions and peripheral neuropathy, although some population-tracking studies report later inception (after 40 years of age)<sup>25</sup>. In relation to cardiac attacks, this may lead to major ventricular hypertrophy, conduction disorders, coronary arterial disease and aortic and mitral valve failure. However, the main symptoms include palpitations, chest pain and dyspnea. Major ventricular failure symptoms are uncommon. In some mutations<sup>25,26</sup> the presence of cardiac attacks is reported. This explains why the disease is investigated in patients with ventricular hypertrophy with no apparent cause. </p>
      <p>Initial investigation may be made with demonstration of low alpha-galactosidase A levels and diagnosis is confirmed with endomyocardial biopsy revealing concentric lamellar bodies in the sarcoplasm of cells<sup>24</sup>. In a less invasive way, TTE may distinguish myocardial hypertrophy found in the Fabry disease from other forms of ventricular hypertrophy by revealing endocardial and subendocardial hyperechoic thickening due to glucolipid deposits. Concomitantly, we observe a parallel hypoechoic thickening along the entire myocardial surroundings. This alteration is called binary appearance of the ventricle endocardial edge<sup>27</sup>. In the case described, the echocardiographic pattern is not similar to the one described for the disease, as well as there is no known family history of diseases connected to chromosome X or family history of ventricular hypertrophy, which are considered highly relevant to investigate the disease<sup>28</sup>.</p>
      <p>Concerning endomyocardial fibrotic diseases as a differential diagnosis for this case, we should remember the endomyocardial fibrosis, an undefined etiology entity prevailing in the tropical zone<sup>29</sup>. </p>
      <p>It is characterized by a fibrotic involvement of the endocardium and adjacent myocardium, apex and ventricular inflow. The fibrotic process often affects papillary muscles determining atrioventricular valve dysfunction. This condition generates ventricular filling restriction, causing the clinical manifestations and hemodynamic disorders suggesting the disease. It also affects both sexes. It has been reported to have affected individuals from 4 to 70 years of age, although it prevails in children and young adults<sup>29</sup>.</p>
      <p>Clinically speaking, patients with endomyocardial fibrosis may present right, left or both HF, depending on the degree of ventricular involvement. One or both atrioventricular valves may often present failure, due to severe involvement of papillary muscles. The inception of the disease is deceitful. The disease seldom stabilizes, leading to progressive myocardial failure. </p>
      <p>A major concern in this disease is that TTE often detects ventricular apex obliteration. Other concerns include dilated atrium, with normal or slightly dilated ventricular cavities. Thickened posterior wall or anterior ventricular septum in patients with left or right ventricle affected, respectively, may also be found<sup>29</sup>. TTE may reveal associated pericardial effusion. The patient described in this case did not present TTE compatible to the classical endomyocardial fibrosis description, due to absence of ventricular apex obliteration, besides diffuse septal thickening suggesting infiltrative disease. Age range little compatible to this condition is also a concern.</p>
      <p>Although the patient was under HF therapy, symptoms persisted, and progressive worsening of renal functions and hypotension were observed. The patient was transferred to the ICU, where she had a cardiorespiratory arrest (CRA), under pulseless electrical activity (PEA). Generally speaking, possible causes of CRA under PEA are: hypoxemia, hypovolemia, hypothermia, hyperkalemia, acidosis, hypoglycemia, acute myocardial infarction, pulmonary thromboembolism, pneumothorax, tamponade, drugs, trauma. Potassium measured on CRA was 5.8 mg/dL, but no description of blood gas measurements or blood glucose. Chest radiography did not reveal pneumothorax, nor other complications deriving from invasive medical procedures. TTE revealed existing alterations, rejected tamponade, but revealed major right ventricular dysfunction described as moderate in previous TTE. Then, we considered pulmonary thromboembolism progressing to shock as the main cause of death. However, although hyperkalemia is not as important, it cannot be disregarded as a decisive factor. (Dr. Odilson Marcos Silvestre, Dr. Henrique Barbosa Ribeiro, Dr. Leonardo Jorge C. de Paula, Dr. S&#233;rgio Ricardo V. Macedo)</p>
      <p><bold>Diagnosis hypothesis: </bold>Systemic amyloidosis with hepatic, renal and cardiac impairments, determining right and left myocardial dysfunction; cardiogenic shock; pulmonary thromboembolism. </p>
      <p>Dr. Odilson Marcos Silvestre,</p>
      <p> Dr. Henrique Barbosa Ribeiro,</p>
      <p> Dr. Leonardo Jorge C. de Paula,</p>
      <p> Dr. S&#233;rgio Ricardo V. Macedo</p>
      <p>
        <bold>Necropsy </bold>
      </p>
      <p>Necropsy revealed light cardiac wall thickening and left ventricular dilation, and moderate right ventricular dilation (<xref ref-type="fig" rid="fig02-body2">Figure 2a</xref>). The entire myocardium was hardened, 'rubber-like' and brownish-yellowish colored. Discreet yellowish granules were observed on the endocardial surface of the left atrium (<xref ref-type="fig" rid="fig02-body2">Figure 2b</xref>, <xref ref-type="fig" rid="fig02-body2">c</xref> and <xref ref-type="fig" rid="fig02-body2">d</xref>). Congestive heart failure signs were also observed, such as: cavity effusions (hydrothorax - with 1.560 mL to the right and 1.200 mL to the left, and hydroperitoneum - with 960 mL, of yellow citrine liquid), as well as chronic passive congestion in lungs and liver. </p>
      <fig id="fig02-body2">
        <graphic xlink:href="1678-4170-abc-93-05-0569-00020-gf02-en.jpg"/></fig>
      <p>Hystological examination of the myocardium revealed plenty of amorphous and pinky deposits within the sarcolemma of myocardiocytes and in the interstice around these, found positive due to the Congo red color (<xref ref-type="fig" rid="fig03-body2">Figure 3</xref>), with bottle-green or apple-green colored refringency through polarized light, consistent with amyloid deposits (<xref ref-type="fig" rid="fig04-body2">Figure 4</xref>). Amyloid deposits were observed in vessels and plain muscles of several organs, such as: lungs (in alveolar septa and vessels); spleen (in periarteriolar areas and close to follicles); kidneys (in vessels); intestines (plain muscles of walls and vessels); thyroid (vessels). </p>
      <fig id="fig03-body2">
        <graphic xlink:href="1678-4170-abc-93-05-0569-00020-gf03-en.jpg"/></fig>
      <fig id="fig04-body2">
        <graphic xlink:href="1678-4170-abc-93-05-0569-00020-gf04-en.jpg"/></fig>
      <p>The bone marrow was investigated for plasma cell dyscrasia. Severe infiltration of plasma cells, moderately well-distinguished totaling around 80% of cell elements. Immunohystochemical study with antibodies for kappa and lambda light chains revealed lambda monoclonal profile of plasma cell infiltration in the bone marrow (<xref ref-type="fig" rid="fig05-body2">Figure 5</xref>). Emboli of plasma cells were observed in lung vessels, which could suggest leukemization. Additionally, kidneys presented the alterations described in cases of multiple myeloma, with diffuse and finely granulose renal surface and, in histology, various hyaline or finely granulose cylinders, in renal marrow tubules. These findings also included alterations of laboratory tests (normocytic normochromic anemia, increase of creatinine and proteinuria).</p>
      <fig id="fig05-body2">
        <graphic xlink:href="1678-4170-abc-93-05-0569-00020-gf05-en.jpg"/></fig>
      <p>Other minor findings for this condition were a hepatic hemangioma, with 1.5 cm and discreet aortic atheromatosis.</p>
      <p>As a terminal cause for the death, we observed right pulmonary thromboembolism, with thromboemboli in lobe artery, with a large hemorrhage area on the right lower lobe, and consequent cardiogenic shock, with cerebral edema (1240g), with slight convexity flattening and hernia of cerebellar amygdalae. </p>
      <p>
        <bold>Dr. Jussara Bianchi Castelli</bold>
      </p>
      <p>
        <bold> Anatomical-pathological diagnoses:</bold>
      </p>
      <p>Malignant neoplasm of lambda plasma cells in the bone marrow, associated to the other anatomical-pathological and laboratory alterations, consistent with diagnosis of multiple myeloma, including primary amyloidosis or systemic AL amyloidosis, with heart deposits (severe), lungs, spleen, kidney, digestive tract and thyroid; right pulmonary thromboembolism; cardiogenic shock; hepatic hemangioma; light aortic atherosclerosis. </p>
      <p>
        <bold>Dr. Jussara Bianchi Castelli</bold>
      </p>
      <p>
        <bold>Comments </bold>
      </p>
      <p>Amyloidosis is associated to multiple diseases involving deposits of proteins with similar appearance (similar physical nature), with variable structural and functional burst of the organ damaged by the deposits<sup>30,31</sup>. In electronic microscopy, X-ray crystallography and infrared spectroscopy, the fibril structure is identical in all types of amyloidosis. The amyloid is composed of fibril proteins (95%) and glycoproteins (5%). However, it differs as to its chemical nature, which included 15 different biochemical forms. The three most common forms are: AL, AA and A&#946;<sup>31</sup>.</p>
      <p>The most common amyloidosis, the AL form (light chain amyloid), is composed of light chain fragments of immunoglobulin. It occurs in 5 to 15% of patients with multiple myeloma and in patients with no myeloma: the latter would have an increase in the number of plasma cells in the bone marrow (plasma cell dyscrasia), which are called monoclonal gammopathies, dysproteinemias or paraproteinemias. Therefore, AL amyloidosis may be present in malignant, benign or pre-malignant conditions (as in the described in this paper). In this type, mature lymphocyte B in monoclonal proliferation produces a single type of immunoglobulin deposit. In primary amyloidosis, around 80% of patients have only the monoclonal immunoglobulin, most of which of lambda type. Bone marrow plasmocytosis is modest, and 20%, multiple myeloma<sup>30,31</sup>.</p>
      <p>The AA form relates to a serum amyloid associated protein derivate produced in the liver in order to provide support to phagocytosis by macrophages. It occurs in combination with chronic inflammatory diseases, such as lepromatous leprosy, tuberculosis, osteomyelitis, bronchiectasis, and rheumatoid arthritis, which may last for years<sup>31</sup>.</p>
      <p>The A&#946; form is found in cerebral lesion (plaques) and in Alzheimer disease vessels. In addition to that, the ATTR amyloidosis (deriving from transtirretin or pre-albumin), a plasmatic protein that carries tiroxin and retinol (vitamin A), which is present in genetically determined disorders (family-derived) and in deposits found in elderly hearts (senile systemic amyloidosis), among other forms that will not be detailed in this study<sup>31</sup>.</p>
      <p>The amyloidosis diagnosis depends on the morphological identification of amyloid in proper tissue samples observed in optical microscopy<sup>31,32</sup>. In clinical suspects, the first step would be the demonstration of amyloid deposits, and abdominal fat biopsy<sup>33,34</sup> has been used and proven positive in 85% of cases of amyloidosis AL<sup>33</sup>. Once the suspected deposit is detected, which is characterized by amorphous material and clear eosinophilic stain on the tissue, it should be analyzed with Congo red color, ideally in 10 &#181;m thick cuts. If this color is positive, it will result in a red tonality, under normal light, and apple-green or bottle-green under polarized light. Then, the amyloid type should be investigated according to the algorithm established<sup>33</sup>. If no family history is reported, type AL is the major suspect, since it comprises most cases. Thus, the investigation carries on by seeking plasma cell dyscrasia through protein survey by immunofixation of blood and urine, besides bone marrow biopsy. Immunofixation replaces the immunoelectrophoresis technique as it is more sensitive and faster, combines electrophoresis and immunoprecipitation techniques which, through antigen-antibody interaction, increases the capacity to identify specific immunoglobulin upon use of specific antibodies. Bone marrow biopsy should be studies with employment of immunohistochemistry for kappa and lambda light chains. If studies are proven negative, the investigation should be directed to the other forms<sup>33</sup>. Determining the type of amyloid is necessary, since the therapy, besides providing support according to the organ affected, should be directed to the root cause to reduce or stop amyloid deposits<sup>33-,35</sup>. Inhibition of amyloid fibrils and anti-amyloid drugs with proteolytic action are two other therapy targets under study<sup>34,35</sup>.</p>
      <p>Prognosis is reserved in generalized AL amyloidosis, with survival of 1 to 2 years<sup>33</sup>. Combined use of autologous bone marrow transplantation and chemotherapy are two therapies used to improve this condition<sup>4,35</sup>. In reactive systemic amyloidosis (AA), prognosis depends on the underlying disorder<sup>33</sup>.</p>
      <p>
        <bold>Dr. Jussara Bianchi Castelli</bold>
      </p>
      <p>
        <bold>References</bold>
      </p>
    </body>
  </sub-article>
  <sub-article article-type="translation" id="TRes" xml:lang="es">
    <front-stub>
      <article-categories/>
      <title-group>
        <article-title xml:lang="es">Caso 5: mujer de 50 A&#241;os con cardiomiopat&#237;a restrictiva, insuficiencia renal y proteinuria</article-title>
      </title-group>
      <kwd-group xml:lang="es">
        <kwd>Amiloidosis</kwd>
        <kwd>cardiomiopat&#237;a restrictiva</kwd>
        <kwd>shock cardiog&#233;nico</kwd>
        <kwd>embolia pulmonar</kwd>
      </kwd-group>
    </front-stub>
    <body>
      <p>
        <bold>CORRELACI&#211;N ANATOMOCL&#205;NICA</bold>
      </p>
      <p><undefined id="title-body3"/>Caso 5 - mujer de 50 a&#241;os con cardiomiopat&#237;a restrictiva, insuficiencia renal y proteinuria</p>
      <p>
        <bold>Odilson Marcos Silvestre; Henrique Barbosa Ribeiro; Leonardo Jorge C. de Paula; S&#233;rgio Ricardo V. Mac&#234;do; Jussara Bianchi Castelli</bold>
      </p>
      <p>Instituto do Cora&#231;&#227;o (InCor) HC-FMUSP, S&#227;o Paulo, SP - Brasil</p>
      <p>Correspondencia</p>
      <p><bold>Palabras clave: </bold>Amiloidosis, cardiomiopat&#237;a restrictiva, shock cardiog&#233;nico, embolia pulmonar.</p>
      <p>Mujer de 50 a&#241;os de edad, natural de Pernambuco y procedente de S&#227;o Paulo, requiri&#243; atenci&#243;n m&#233;dica por disnea desencadenada por esfuerzos peque&#241;os.</p>
      <p>Hace 4 meses hubo aparici&#243;n de disnea desencadenada a esfuerzos medios, que desde hace 2 meses hab&#237;a desarrollado esfuerzos m&#237;nimos y ortopnea. Adem&#225;s de ello, present&#243; edema de miembros inferiores. Requiri&#243; atenci&#243;n m&#233;dica, recibi&#243; el diagn&#243;stico de insuficiencia cardiaca y se intern&#243; para tratamiento. La paciente sab&#237;a que era portadora de hipotiroidismo desde hace a&#241;os.</p>
      <p>Durante la internaci&#243;n se someti&#243; a la toracocentesis para drenaje de derramen pleural. El an&#225;lisis bioqu&#237;mico del l&#237;quido pleural (6 Dic 2007) revel&#243; deshidrogenasa l&#225;ctica (DHL) (derrame pleural/suero) 104/216 = 0,48; prote&#237;na (derrame pleural/suero) 2,8/6,2 = 0,45; gradiente de albumina = 1,5.</p>
      <p>La paciente recibi&#243; alta hospitalaria con prescripci&#243;n de 80 mg de furosemida, 50 mg de espironolactona, 75 mg de captopril, 100 &#181;g de levotiroxina diariamente, adem&#225;s de 0,25 mg, en d&#237;as alternados, de digoxina.</p>
      <p>Aunque ante la mejora de la disnea, despu&#233;s del alta la paciente present&#243; nuevo empeoramiento del cuadro con disnea a los esfuerzos menores que los habituales y busc&#243; atenci&#243;n en este Hospital.</p>
      <p>El examen f&#237;sico (9 Ene 2008) revel&#243; paciente eupneica, con incremento de la presi&#243;n venosa yugular, frecuencia cardiaca de 100 lpm y presi&#243;n arterial 90/80 mm Hg. El examen de los pulmones revel&#243; disminuci&#243;n de murmullo vesicular en el tercio medio del hemit&#243;rax derecho y abolici&#243;n en el tercio inferior de ambos hemit&#243;rax. La semiolog&#237;a cardiaca revel&#243; 4&#186; ruido, no hab&#237;a soplos o atrito peric&#225;rdico. El abdomen era doloroso a la percusi&#243;n y palpaci&#243;n en hipocondrio derecho. El h&#237;gado se palp&#243; a 10 cm del reborde costal derecho; hab&#237;a edema +++/4+ en miembros inferiores.</p>
      <p>La radiograf&#237;a de t&#243;rax (9 Ene 2008) revel&#243; gran derrame pleural bilateral.</p>
      <p>El ECG (14 Ene 2008) revel&#243; ritmo sinusal, frecuencia cardiaca 100 lpm, sobrecarga atrial izquierda, se&#241;ales indirectas de sobrecarga atrial derecha (Pe&#241;aloza-Tranchesi), bajo voltaje del QRS en el plano frontal, onda R poco progresiva de V<sub>1</sub> a V<sub>4</sub> (<xref ref-type="fig" rid="fig01-body3">Figura 1</xref>).</p>
      <fig id="fig01-body3">
        <graphic xlink:href="1678-4170-abc-93-05-0569-00020-gf01-es.jpg"/></fig>
      <p>Los ex&#225;menes de laboratorio (9 Ene 2008) revelaron elevaci&#243;n de la creatinina (<xref ref-type="table" rid="tab01-body3">Tabla 1</xref>).</p>
      <table-wrap id="tab01-body3">
        <graphic xlink:href="1678-4170-abc-93-05-0569-00020-gt01-es.jpg"/></table-wrap>
      <p>El ecocardiograma (10 Ene 2008) revel&#243;: aorta 29 mm, atrio izquierdo 41 mm, di&#225;metro diast&#243;lico de ventr&#237;culo derecho 29 mm, dimensiones del ventr&#237;culo izquierdo (di&#225;stole/s&#237;stole) 38 mm/28 mm, espesores septo interventricular y pared posterior de 13 mm y fracci&#243;n de eyecci&#243;n del ventr&#237;culo izquierdo del 52%. Se hizo el diagn&#243;stico de hipertrofia conc&#233;ntrica de grado moderado. Hab&#237;a hiperrefringencia del septo interventricular. La funci&#243;n ventricular sist&#243;lica estaba disminuida a expensas de hipocinesia difusa. Los hallazgos del Doppler fueron compatibles con el est&#225;ndar restrictivo sin reversi&#243;n tras la maniobra de Valsalva. El ventr&#237;culo derecho demostr&#243; hipertrofia discreta e hipocinesia moderada y hab&#237;a insuficiencia tric&#250;spide acentuada.</p>
      <p>Se realiz&#243; punci&#243;n y drenaje de derrame pleural e se instituy&#243; la terapeutica para insuficiencia cardiaca, con utilizaci&#243;n de furosemida por v&#237;a endovenosa y mantenimiento de las medicaciones en uso.</p>
      <p>Una nueva evaluaci&#243;n del l&#237;quido pleural (16 Ene 08) revel&#243; las razones de DHL (derrame pleural/suero) 120/210 = 0,57; prote&#237;nas (derramen pleural/suero) 3,6/6,7=0,54; gradiente de albumina= 1.2, 440 leuc&#243;citos/mm&#179;, colesterol &lt;50 mg/dl, glucosa 119 mg/dl</p>
      <p>La ultrasonograf&#237;a de abdome (14 Ene 08) revel&#243; &#225;rea hiperecogencia en lobo hep&#225;tico, cuyo aspecto ultrasonogr&#225;fico era compatible con hemangioma; adem&#225;s de ascitis de peque&#241;o volumen y derramen pleural bilateral. No hab&#237;a otras alteraciones.</p>
      <p>La ultrasonograf&#237;a de v&#237;a urinarias (22 Ene 2008) se hall&#243; normal.</p>
      <p>La tomograf&#237;a de t&#243;rax (17 Ene 2008) revel&#243; volumoso derrame pleural bilateral con atelectasia de los lobos inferiores y de los segmentos posteriores de los lobos superiores.</p>
      <p>Pese a la mejora de la disnea hubo persistencia del derrame pleural a la derecha y progresivo empeoramiento de la funci&#243;n renal (<xref ref-type="table" rid="tab01-body3">Tab. 1</xref>), con paciente manteniendo siempre presi&#243;n arterial de 90/60 mm Hg. Se suspendieron los diur&#233;ticos, captopril y digoxina y se inici&#243; el uso de dobutamina; se indic&#243; hemodi&#225;lisis y se traslad&#243; a la paciente a la unidad de cuidados Intensivos.</p>
      <p>La bi&#243;psia de piel (16 Ene 08) fue negativa para la sustancia amiloides (tinci&#243;n rojo-Congo).</p>
      <p>Por la noche del 27 de enero de 2008 present&#243; parada cardiaca en actividad el&#233;ctrica sin pulso que se recuper&#243;. La paciente evolucion&#243; hipotensa. Se llev&#243; a cabo un nuevo ecocardiograma para descartar tamponamento cardiaco, el que revel&#243; ventr&#237;culo izquierdo con hipertrofia conc&#233;ntrica de grado discreto e hiperrefringencia del septo, sugestiva de proceso infiltrativo, y funci&#243;n sist&#243;lica disminuida a expensas de hipocinesia difusa. El ventr&#237;culo derecho ten&#237;a hipocinesia acentuada y derrame peric&#225;rdico de grado discreto a moderado</p>
      <p>Se efectu&#243; la punci&#243;n tor&#225;cica a la derecha y no hab&#237;a se&#241;ales de hemot&#243;rax. La radiograf&#237;a de t&#243;rax tras los cat&#233;teres centrales no revel&#243; neumot&#243;rax. Cerca de una hora tras la parada cardiaca inicial hubo nueva parada en actividad el&#233;ctrica sin pulso, esta irreversible (27 Ene 2008).</p>
      <p>
        <bold>Aspectos cl&#237;nicos</bold>
      </p>
      <p>El caso descripto est&#225; referido a una mujer de 50 a&#241;os de edad con historia de hipotireoidismo, que present&#243; disnea progresiva en los &#250;ltimos cuatro meses pese al tratamiento para insuficiencia cardiaca.</p>
      <p>La insuficiencia cardiaca (IC) constitui diagn&#243;stico cl&#237;nico que se hizo por la recopilaci&#243;n de datos de la anamnesis y examen f&#237;sico<sup>1</sup>. La historia cl&#237;nica de la IC se caracteriza por disnea o cansancio a los esfuerzos. Ortopnea y disnea parox&#237;stica nocturna son hallazgos m&#225;s espec&#237;ficos para el diagn&#243;stico de este s&#237;ndrome. Se resalta la importancia de la b&#250;squeda de factores de riesgo o de enfermedad cardiovascular previa. El examen f&#237;sico tiene mayor contribuci&#243;n en la IC descompensada, ya que la sensibilidad es baja cuando est&#225; compensada. Las alteraciones est&#225;n relacionadas a la congesti&#243;n o a la cardiomegalia, adem&#225;s de hallazgos que pueden sugerir la enfermedad cardiaca. De esta manera, se deben buscar en la evaluaci&#243;n propedeutica edema perif&#233;rico, taquicardia en reposo, estertores pulmonares, turgencia venosa yugular, reflujo hepatoyugular, hepatomegalia, &#237;ctus desviado y ruidos accesorios. La presencia de soplos o golpe (knock) peric&#225;rdico, respectivamente<sup>2 </sup>puede denunciar la enfermedad valvular o peric&#225;rdica.</p>
      <p>La paciente en cuesti&#243;n tiene una historia de disnea relacionada a los esfuerzos que progresion&#243; a lo largo del tiempo, culminando con los s&#237;ntomas a los m&#237;nimos esfuerzos, ortopnea y necesidad de internaci&#243;n. Es importante que se resalte la no descripci&#243;n de factores de riesgo cardiovasculares ni enfermedad cardiaca previa. La prueba f&#237;sica revel&#243; importantes hallazgos para el diagn&#243;stico del s&#237;ndrome y tambi&#233;n datos para el in&#237;cio de la reflexi&#243;n acerca de la etiolog&#237;a de la IC. LA presencia de taquicardia en el reposo es un hallazgo com&#250;n, pero de poca especificidad para el diagn&#243;stico. No hay descripci&#243;n del &#237;ctus cardiaco, dato de importancia diagn&#243;stica incuestionable. El relato de turgencia venosa yugular, hepatomegal&#237;a y el edema perif&#233;rico nos llevan a pensar en congesti&#243;n sist&#233;mica, es decir, insuficiencia cardiaca derecha. Se debe resaltar que la presencia de turgencia venosa yugular y de presi&#243;n de pulso disminuida (PA 90 x 80 mmHg) determinan el empeoramiento pron&#243;stico al caso. La presencia del cuarto ruido sugiere disfunci&#243;n diast&#243;lica del miocardio. Vale recordar que la hepatomegalia acentuada puede sugerir, adem&#225;s de la congesti&#243;n, infiltraci&#243;n del tejido hep&#225;tico. Los hallazgos de la propedeutica evidencian a&#250;n la existencia de derrame pleural bilateral, principalmente a la derecha, as&#237; como ocurre generalmente en la IC. Probablemente el derrame haya aportado al surgimiento de la disnea. El an&#225;lisis del l&#237;quido pleural se llev&#243; a cabo en dos momentos. Al inicio de la internaci&#243;n, el primero an&#225;lisis a la luz de los criterios de Light caracteriz&#243; el l&#237;quido como transudato, lo que corrobora la afirmativa de derrame secundario a la IC. Sin embargo, en la segunda punci&#243;n, el l&#237;quido tiene par&#225;metros que sugieren exsudato, pero vale notar que en este momento la paciente estaba en uso de diur&#233;ticos, lo que puede explicar la modificaci&#243;n bioqu&#237;mica del l&#237;quido.</p>
      <p>Los datos de anamnesis y examen f&#237;sico posibilitan el diagn&#243;stico sindr&#243;mico de IC. No obstante, la historia cl&#237;nica no revela datos que puedan sugerir la etiolog&#237;a, ya que no hay relato de hipertensi&#243;n, enfermedad isqu&#233;mica o aun factores de riesgo cardiovasculares. La prueba f&#237;sica nos se&#241;ala un predom&#237;nio de hallazgos compatibles con IC derecha.</p>
      <p>En el an&#225;lisis de los ex&#225;menes complementarios, la radiograf&#237;a de t&#243;rax confirm&#243; la presencia de gran derrame pleural bilateral, pero no hubo relato del tama&#241;o del &#225;rea cardiaca.</p>
      <p>Los ex&#225;menes laboratoriales de ingreso revelaron ausencia de alteraci&#243;n consistente en las series hematol&#243;gicas. La dosificaci&#243;n de hormonas tiroideas evidenci&#243; que el hipotireoidismo estaba compensado. La funci&#243;n renal estuvo alterada desde el in&#237;cio, siempre con una relaci&#243;n urea: creatinina &gt; 40, sugeriendo est&#225;ndar pre renal. Sin embargo, la presencia de proteinuria patol&#243;gica en la urina de 24 horas sugiere enfermedad del par&#233;nquima renal. El aumento progresivo de las escorias nitrogenadas posiblemente estuvo relacionado al uso de diur&#233;ticos durante la internaci&#243;n.</p>
      <p>El electrocardiograma inicial evidenciaba se&#241;ales de sobrecarga biatrial, bajo voltaje del QRS en la cr&#243;nica, adem&#225;s de la onda R que poco progresaba de V1 a V4. Entre las condiciones que cursan con bajo voltaje del QRS tenemos derrame peric&#225;rdico, enfermedad pulmonar obstructiva cr&#243;nica e hipotiroidismo. Todav&#237;a ninguna de ellas justifica aumento de la masa cardiaca que se detect&#243; por el ecocardiograma transtor&#225;cico (ETT). A ello se a&#241;adi&#243; la ausencia de derrame peric&#225;rdico al ETT, la ausencia de antecediente de enfermedad obstructiva pulmonar cr&#243;nica, as&#237; como TSH y T4 libre normales. Por otro lado, el aumento de la masa mioc&#225;rdica, en funci&#243;n de condiciones como hipertensi&#243;n o cardiomiopat&#237;a hipertr&#243;fica, se asocia al voltaje normal o aumentado en el electrocardiograma, lo que no se observ&#243; en nuestro caso. De este modo, la presencia de hipertrof&#237;a al ETT, asociada al bajo voltaje electrocardiogr&#225;fico son hallazgos exclusivos de las enfermedades mioc&#225;rdicas infiltrativas<sup>3, 4</sup>.</p>
      <p>La amiloidosis en hasta el 50% de los pacientes puede determinar al ECG un bajo voltaje del QRS en derivaciones de miembros<sup>4, 5</sup>. Otra alteraci&#243;n muy frecuente en esta enfermedad es la presencia de est&#225;ndar de pseudoinfarto. Tanto en la amiloidosis, como en las dem&#225;s enfermedades infiltrativas del coraz&#243;n, como la hemocromatosis, sarcoidosis o la enfermedad de Fabry, son comunes los disturbios de conducci&#243;n, muchas veces con bloqueos avanzados, lo que no se verific&#243; en nuestro caso. Adem&#225;s de ello, estas referidas enfermedades tambi&#233;n cursan con fibrilaci&#243;n atrial parox&#237;stica o persistente, especialmente la amiloidosis y la enfermedad de Fabry, lo que tambi&#233;n no pudimos observar.</p>
      <p>Las enfermedades infiltrativas mioc&#225;rdicas al principio llevan la disfunci&#243;n diast&#243;lica asociada a la hipertrofia de pared, siendo que la disfunci&#243;n diast&#243;lica de ventr&#237;culo derecho tambi&#233;n puede ocurrir<sup>6</sup>. En casos m&#225;s avanzados, hay la progresi&#243;n de la hipertrof&#237;a de pared, que resulta en cardiomiopat&#237;a restrictiva, con cavidad ventricular izquierda no dilatada y peque&#241;a<sup>6</sup>. Este est&#225;ndar, aliado al aumento biatrial son asimismo m&#225;s frecuentes en la amiloidosis, ya que en la sarcoidosis, y sobre todo en la hemocromatosis, la dilataci&#243;n del ventr&#237;culo izquierdo es m&#225;s prevalente.</p>
      <p>Otros factores importantes obtenidos para el diagn&#243;stico diferencial a partir del ETT son la presencia de miocardio 'cintilante', y ausencia de valvulopat&#237;a importante (solamente espesor de las c&#250;spides) que est&#225;n presentes en la amiloidosis. El miocardio cintilante es un hallazgo poco sensible (el 26% en una serie) y no puede utilizarse para descartar la amiloidosis<sup>4</sup>. Por otro lado, la dilataci&#243;n del ventr&#237;culo derecho, m&#225;s all&#225; de considerarse como pron&#243;stica en la amiloidosis, aliada al aumento de las presiones de llenado, justifica la insuficiencia tric&#250;spide muchas veces presente, como en nuestro caso. Otras enfermedades infiltrativas miocardicas, como la sarcoidosis y la enfermedad de Fabry pueden cursar con valvulopat&#237;a espec&#237;ficamente mitral y a&#243;rtica<sup>6</sup>.</p>
      <p>Ante los datos presentados hasta el momento, consideramos la amiloidosis como principal hip&#243;tesis. &#201;sta consiste en un grupo heterog&#233;neo de des&#243;rdenes heredit&#225;rias, inflamat&#243;rias, o neopl&#225;sicas, que resultan en dep&#243;sitos de fibrillas amiloides en diversos &#243;rganos, tales como coraz&#243;n, ri&#241;ones y sistema nervioso. Se consideran las fibrillas amiloides como subunidades proteicas de bajo peso molecular derivadas de prote&#237;nas s&#233;ricas normales o aberrantes<sup>7</sup>. El acometimiento cardiaco se debe a la infiltraci&#243;n mioc&#225;rdica de estas proteinas, por mecanismos patog&#233;nicos diferentes, volvi&#233;ndose cl&#237;nicamente apariente cuando el dep&#243;sito extracelular de amiloides altera la arquitectura del tejido normal<sup>7</sup>.</p>
      <p>En las enfermedades infiltrativas, muchas veces la etiolog&#237;a se confirma por la bi&#243;psia endomioc&#225;rdica. Esto puede ocurrir, por ejemplo, por la tinci&#243;n con rojo-Congo de los dep&#243;sitos amiloides, en la amiloidosis; granulomas sarco&#237;dicos, en la sarcoidosis; y corp&#250;sculos lamelares en la enfermedad de Fabry. Sin embargo, la bi&#243;psia endomioc&#225;rdica presenta complicaciones y muchas veces no se la puede realizar. En este sentido, otras modalidades diagn&#243;sticas se deben utilizar. En el caso de la amiloidosis esto se puede llevar a cabo mediante la demostraci&#243;n de dep&#243;sitos amiloides en el examen histopatol&#243;gico de bi&#243;psias extra&#237;das de tejidos como grasa abdominal, reto o de los ri&#241;ones. En esa paciente, se recolect&#243; una muestra del tejido celular subcut&#225;neo, sin embargo result&#243; negativo para sustancia amiloide. En trabajos retrospectivos la sensibilidad del examen es bastante alta, espec&#237;ficamente cuando se utilizan diversas muestras (cercanas al 100% cuando se llevaban a cabo 4 muestras como m&#237;nimo)<sup>8</sup>.</p>
      <p>Otro examen bastante elucidativo en las cardiopat&#237;as infiltrativas es la resonancia nuclear magn&#233;tica que, en este caso, no hay descripci&#243;n de su realizaci&#243;n, posiblemente por el riesgo renal presentada, con disfunci&#243;n de evoluci&#243;n para fibrosis nefrog&#233;nica sist&#233;mica.</p>
      <p>En suma, tenemos el caso de una paciente del sexo enfermedad de 50 a&#241;os, sin historia previa de femenino cardiovascular o comorbidades conocidas, que evolucion&#243; hacia disnea r&#225;pidamente progresiva llegando a m&#237;nimos esfuerzos, asociada a ortopnea y congesti&#243;n sist&#233;mica (aumento del volume hep&#225;tico y edema de miembros inferiores). Presentaba s&#237;ntomas inespec&#237;ficos, pero al ETT se evidenci&#243; la hipertrof&#237;a ventricular, hiperrefringencia del septo ventricular y est&#225;ndar restrictivo al Doppler, hallazgos estos compatibles con procesos infiltrativos mioc&#225;rdicos. Ante la presentaci&#243;n cl&#237;nica, alteraciones electrocardiogr&#225;ficas y ecocardiogr&#225;ficas, presencia de proteinuria y hepatomegal&#237;a, la amiloidosis se vuelve en la principal hip&#243;tesis diagn&#243;stica. Sin embargo, otras enfermedades infiltrativas mioc&#225;rdicas se deben investigar asimismo, en funci&#243;n de los s&#237;ntomas presentados y espec&#237;ficamente mediante el hecho de la bi&#243;psia de tejido celular subcut&#225;neo haber sido negativa.</p>
      <p>Las enfermedades infiltrativas mioc&#225;rdicas se clasifican en el grupo de las cardiopat&#237;as restrictivas, siendo &#233;stas caracterizadas por la rigidez de las paredes mioc&#225;rdicas asociadas a la no complacencia de uno o de ambos ventr&#237;culos, siendo m&#225;s com&#250;n la implicaci&#243;n del ventr&#237;culo izquierdo, conllevando el llenado ventricular inadecuado y consecuente incremento de la presi&#243;n diast&#243;lica final<sup>9</sup>.</p>
      <p>Este grupo de cardiomiopat&#237;as se divide en tres clases distintas entre s&#237;:</p>
      <p>1) las infiltraciones mioc&#225;rdicas, en la que el miocardio se infiltra mediante una sustancia anormal (como en la amiloidosis, sarcoidosis, hemocromatosis y enfermedad de Fabry);</p>
      <p>2) las afecciones fibr&#243;ticas del mioc&#225;rdio, con extensi&#243;n fibrosis por toda pared mioc&#225;rdica (cardiomiopat&#237;a familiar e idiop&#225;tica);</p>
      <p>3) las afecciones fibr&#243;ticas endomioc&#225;rdicas, en la que hay acometimiento principalmente del endoc&#225;rdio y subendoc&#225;rdio (enfermedades (EMF), s&#237;ndrome hipereosinof&#237;lico y met&#225;stases de endomiocardiofibrosis tumorales)<sup>9</sup>.</p>
      <p>Entre las enfermedades infiltrativas del coraz&#243;n debemos recordar la sarcoidosis cardiaca como diagn&#243;stico diferencial. &#201;sta es una enfermedad sist&#233;mica, de etiolog&#237;a desconocida, que se caracteriza por la formaci&#243;n de granulomas no caseosos en cualquier &#243;rgano del cuerpo, conllevando desarreglo de las estructuras tisulares<sup>10</sup>. Generalmente, el diagn&#243;stico de la enfermedad cardiaca se hace tras algunos a&#241;os del desarrollo de s&#237;ntomas relacionados a la disfunci&#243;n de otros &#243;rganos (pulm&#243;n, h&#237;gado, piel y ojos). No obstante, en una minor&#237;a de pacientes puede haber acometimiento cardiaco puro, sin cualquier otra manifestaci&#243;n de la enfermedad<sup>11</sup>. El acometimiento cardiaco ocurre en hasta el 30% de los pacientes, pese a que s&#243;lo el 5% de ellos manifiesta cl&#237;nicamente la enfermedad, y &#233;sta se caracteriza por bloqueos atrioventriculares avanzados y espesor anormal de la pared<sup>12-14</sup>. Casi la totalidad de los pacientes presenta acometimiento del trato respiratorio, manifest&#225;ndose como linfadenopat&#237;a hiliar e infiltrado pulmonar intersticial. La linfadenopat&#237;a hiliar acomete el 90% de los individuos con la enfermedad. De este modo, a partir de la presentaci&#243;n cl&#237;nica y radiol&#243;gica del paciente, puede sopecharse del diagn&#243;stico, sin embargo la confirmaci&#243;n se debe hacerse a partir de bi&#243;psia con demostraci&#243;n de granulomas no caseosos<sup>15</sup>.</p>
      <p>Adem&#225;s de la disfunci&#243;n cardiaca la paciente en cuesti&#243;n presentaba hepatomegalia con im&#225;genes hiperecog&#233;nicas semejantes a hemangiomas. En la sarcoidosis, ocurre raramente la disfunci&#243;n hep&#225;tica importante, pero puede haber discreto aumento de enzimas hep&#225;ticas y aumento m&#225;s importante de enzimas canaliculares, lo que por veces puede llevar a s&#237;ntomas de hipertensi&#243;n portal<sup>10</sup>. En la evoluci&#243;n del caso, ante las hip&#243;tesis diagn&#243;sticas, podr&#237;a haber sido realizada bi&#243;psia hep&#225;tica o mioc&#225;rdica, ya que el hallazgo de granulomas sella el diagn&#243;stico. No obstante, el resultado falso negativo puede ocurrir debido al hecho del acometimiento no ser homog&#233;neo, principalmente en la afecci&#243;n cardiaca<sup>16</sup>. Lo que opera en contra el diagn&#243;stico de sarcoidosis cardiaca en la paciente es la presencia de hiperrefring&#233;ncia del septo en el ETT, ya que en la sarcoidosis las alteraciones son inespec&#237;ficas, pudi&#233;dose encontrar aneurisma ventricular, dilataci&#243;n de la cavidad y espesor de pared<sup>17</sup>.</p>
      <p>Otro diagn&#243;stico diferencial posible es la hemocromatosis hereditaria. Ella est&#225; caracterizada como enfermedad autos&#243;mica recesiva en la que la mutaci&#243;n en el gene HEF causa aumento de la absorci&#243;n intestinal de hierro, llevando a manifestaciones cl&#237;nicas secund&#225;rias al exceso de dep&#243;sito de hierro en los tejidos, especialmente h&#237;gado, coraz&#243;n, p&#225;ncreas e hip&#243;fisis<sup>18</sup>. El modo heterozigoto de la enfermedad normalmente no se manifiesta cl&#237;nicamente durante la vida, pudiendo ser un hallazgo a partir de la dosificaci&#243;n de la saturaci&#243;n de la transferrina (raz&#243;n entre la concentraci&#243;n de hierro s&#233;rico por la capacidad total de uni&#243;n al hierro)<sup>19</sup>. Sin embargo, la forma homozigota puede llevar la manifestaciones severas de la enfermedad, generalmente tras los 40 a&#241;os de edad, y es m&#225;s tard&#237;o en el sexo femenino debido a las p&#233;rdidas menstruales en la fase pre menopausa<sup>20, 21</sup>. Las manifestaciones m&#225;s frecuentes son alteraciones de la funci&#243;n hep&#225;tica, letarg&#237;a, hiperpigmentaci&#243;n cut&#225;nea, diabetes mellitus y anormalidades electrocardiogr&#225;ficas<sup>22</sup>. Los dist&#250;rbios cardiacos m&#225;s comunes son la dilataci&#243;n ventricular caracterizada por el desarrollo de insuficiencia cardiaca y disturbios de conducci&#243;n<sup>23</sup>. La hipertrof&#237;a ventricular no es caracter&#237;stica, as&#237; como la hiperrefringencia al ETT. En el caso expuesto, adem&#225;s de la disfunci&#243;n cardiaca no ser t&#237;pica, la dosificaci&#243;n s&#233;rica de hierro y ferritina eran normales, hechos estos que excluden el diagn&#243;stico.</p>
      <p>En la investigaci&#243;n de la paciente, un diagn&#243;stico menos probable, pero que se debe notar es la enfermedad de Fabry. Es una enfermedad de dep&#243;sito de glicolip&#237;deos relacionada al cromosoma X que se ocasiona pr la actividad deficiente de la enzima liposomal Alfa-galactosidasis A, conllevando la acumulaci&#243;n y el dep&#243;sito tisular subsiguiente de globotriaosilceramida<sup>24</sup>. Una caracter&#237;stica importante es que la manifestaci&#243;n cl&#237;nica generalmente ocurre antes de los 10 a&#241;os de edad, incluyendo lesiones cut&#225;neas y neuropat&#237;a perif&#233;rica, pese a que algunos estudios de rastreo poblacional evidenc&#237;an su inicio m&#225;s tard&#237;o (tras los 40 a&#241;os de edad)<sup>25</sup>. Con relaci&#243;n al acometimiento cardiaco, este puede llevar a hipertrof&#237;a ventricular importante, defectos de conducci&#243;n, enfermedad arterial coronaria e insuficiencia de las valvulas a&#243;rtica y mitral. No obstante, los principales s&#237;ntomas son de palpitaciones, angina de pecho y disnea, siendo mucho incomunes los s&#237;ntomas importantes de falla ventricular. Se resalta la presencia de acometimiento cardiaco aislado en algumas mutaciones<sup>25, 26</sup>. Este hecho explica la razi&#243;n de realizarse el rastreo de la enfermedad en pacientes con hipertrof&#237;a ventricular aislada sin otra causa aparente.</p>
      <p>La investigaci&#243;n inicial se puede realizar con la demostraci&#243;n de bajos niveles de alfa-galactosidasa A y el diagn&#243;stico confirmado con bi&#243;psia endomioc&#225;rdica evidenciando cuerpos lamelares conc&#233;ntricos en el tecido sarcoplasm&#225;tico de las c&#233;lulas<sup>24</sup>. De modo menos invasivo, el ETT puede distinguir la hipertrof&#237;a mioc&#225;rdica de la enfermedad de Fabry de otras formas de hipertrof&#237;a ventricular, a partir de la demostraci&#243;n de espesor hiperecog&#233;nico del endocardio y subendoc&#225;rdio por la deposici&#243;n glicolip&#237;dica. A la vez, hay engrosamiento hipoecog&#233;nico en paralelo a lo largo de todo el contorno mioc&#225;rdico, alteraci&#243;n que se denomina de aparencia binaria de borde endoc&#225;rdico del ventr&#237;culo<sup>27</sup>. En el caso expuesto, el est&#225;ndar ecocardiogr&#225;fico no se asemeja al descripo para la enfermedad, as&#237; como no hay historia familiar sabida de enfermedades relacionadas al cromosomo X o la historia familiar de hipertrof&#237;a ventricular, datos considerados como de maior relevancia para la realizaci&#243;n de investigaci&#243;n de la enfermedad<sup>28</sup>.</p>
      <p>Respecto a las afecciones fibr&#243;ticas endomioc&#225;rdicas como diagn&#243;stico diferencial del presente caso, se debe notar la endomiocardiofibrosis, la entidad de etiolog&#237;a indefinida, prevalente en la zona de los tr&#243;picos<sup>29</sup>. Se caracteriza por la envoltura fibr&#243;tica del endocardio y el miocardio adyacente, el &#225;pice y la v&#237;a de entrada de los ventr&#237;culos. El proceso fibr&#243;tico afecta frecuentemente los m&#250;sculos papilares determinanado la disfunci&#243;n de las v&#225;lvulas atrioventriculares. Este cuadro genera restricci&#243;n al llenado ventricular, ocasionando las manifestaciones cl&#237;nicas y des&#243;rdenes hemodin&#225;micas sugestivas de la enfermedad. Incide igualmente en ambos sexos, habiendo sido descripta en sujetos de los 4 a los 70 a&#241;os, a pesar de su mayor prevalencia en ni&#241;os y adultos j&#243;venes<sup>29</sup>.</p>
      <p>Cl&#237;nicamente, el paciente con EMF se puede presentar con manifestaciones de IC derecha, izquierda o ambas, dependiendo del grado de envoltura de los ventr&#237;culos. Frecuentemente ocurre insuficiencia de una o ambas v&#225;lvulas atrioventriculares, por la afectaci&#243;n de los m&#250;sculos papilares. El in&#237;cio de la enfermedad es normalmente insidioso, raramente la enfermedad puede estabilizarse, evolucionando con falla mioc&#225;rdica progresiva.</p>
      <p>La obliteraci&#243;n del &#225;pice del ventr&#237;culo implicado al ETT es un punto principal de la enfermedad, adem&#225;s de &#225;trios dilatados, con cavidades ventriculares normales o discretamente dilatadas. Tambi&#233;n hay engrosamiento de la pared posterior o del septo ventricular anterior en pacientes con envoltura del ventr&#237;culo izquierdo o derecho, respectivamente<sup>29</sup>. El ETT puede evidenciar derrame pericardico asociado. La paciente del caso no presentaba ETT compatible con la descripci&#243;n cl&#225;sica de la EMF, debido a la ausencia de imagen de obliteraci&#243;n de los apices ventriculares, adem&#225;s de demostrar engrosamiento difuso del septo, lo que sugiere enfermedad infiltrativa. Se a&#241;ade a ello el grupo de edad poco compatible con el cuadro.</p>
      <p>En la evoluci&#243;n de la paciente, a pesar del tratamiento cl&#237;nico para la IC, hubo persistencia de los s&#237;ntomas, progresivo empeoramiento de la funci&#243;n renal e hipotensi&#243;n. Se traslad&#243; la paciente a la unidad de cuidados intensivos, donde evolucion&#243; con parada cardiorrespirat&#243;ria (PCR), en actividad el&#233;ctrica sin pulso (AESP). De modo general, las posibles causas de la PCR en AESP son: hipoxemia, hipovolemia, hipotermia, hipercalemia, acidosis, infarto agudo de miocardio, hipoglucemia, tromboembolismo pulmonar, pneumot&#243;rax, tamponamento, drogas, trauma. El pot&#225;sio dosificado al d&#237;a de la PCR era de 5,8 mg/dL, siendo que no hay descripci&#243;n de gasometr&#237;a o glucemia. La investigaci&#243;n que se hizo con la radiograf&#237;a de t&#243;rax no demostr&#243; neumot&#243;rax, ni tampoco otras complicaciones advenidas de procedimiento m&#233;dico invasivo. El ETT revel&#243; las alteraciones ya existentes, descart&#243; tamponamiento, sin embargo evidenci&#243; disfunci&#243;n derecha importante que hab&#237;a sido descripta como moderada en ETT previo. De esta manera, consideramos como TEP con evoluci&#243;n hacia el shock la principal hip&#243;tesis para la causa mortis. Sin embargo, la hipercalemia, pese a que no sea tan importante, tambi&#233;n no se puede descartar como factor decisivo.</p>
      <p>Dr. Odilson Marcos Silvestre,</p>
      <p> Dr. Henrique Barbosa Ribeiro,</p>
      <p> Dr. Leonardo Jorge C. de Paula,</p>
      <p> Dr. S&#233;rgio Ricardo V. Macedo</p>
      <p><bold>Hip&#243;tesis diagn&#243;stica: </bold>amiloidosis sist&#233;mica con afectaci&#243;n hep&#225;tica, renal y card&#237;aca, determinando disfunci&#243;n mioc&#225;rdica derecha e izquierda; shock cardiog&#233;nico; tromboembolismo pulmonar.</p>
      <p>Dr. Odilson Marcos Silvestre,</p>
      <p> Dr. Henrique Barbosa Ribeiro,</p>
      <p> Dr. Leonardo Jorge C. de Paula,</p>
      <p> Dr. S&#233;rgio Ricardo V. Macedo</p>
      <p>
        <bold>Necropsia</bold>
      </p>
      <p>En la necropsia, el coraz&#243;n presentaba aumento del espesor de las paredes y dilataci&#243;n del ventr&#237;culo izquierdo leves y, el mismo, en grado moderado, en el ventr&#237;culo derecho (<xref ref-type="fig" rid="fig02-body3">Figura 2a</xref>). El mioc&#225;rdio como un todo se presentaba r&#237;gido, con una apariencia de caucho y una tonalidad casta&#241;a amarillenta, y se notaba a&#250;n granulosidades amarillentas discretas en la superficie endoc&#225;rdica del &#225;trio izquierdo (<xref ref-type="fig" rid="fig02-body3">b</xref>, <xref ref-type="fig" rid="fig02-body3">c</xref> y <xref ref-type="fig" rid="fig02-body3">d</xref>). Se constataron tambi&#233;n se&#241;ales de insuficiencia cardiaca congestiva, tales como: derramenes cavit&#225;rios (hidrot&#243;rax - con 1.560 mL a la derecha y 1.200 mL a la izquierda, y hidroperitonio - con 960 mL, de l&#237;quido amarillo-citrino), as&#237; como aspecto de congesti&#243;n pasiva cr&#243;nica en pulmones e h&#237;gado.</p>
      <fig id="fig02-body3">
        <graphic xlink:href="1678-4170-abc-93-05-0569-00020-gf02-es.jpg"/></fig>
      <p>El examen histol&#243;gico del mioc&#225;rdio revel&#243; abundante dep&#243;sito de material amorfo y color rosa dentro del sarcolema de los miocardiocitos y en el intersticio cerca de estos, que fue positivo por la tinci&#243;n de rojo-Congo (<xref ref-type="fig" rid="fig03-body3">Figura 3</xref>), con refringencia en tonalidad verde botella o verde manzana por la luz polarizada, consistente con el dep&#243;sito amiloides (<xref ref-type="fig" rid="fig04-body3">Figura 4</xref>). La deposici&#243;n amiloides se observ&#243;, todav&#237;a, en vasos y musculatura lisa de m&#250;ltiples &#243;rganos, tales como: pulmones (en septos alveolares y vasos); bazo (en regiones periarteriolares y junto a fol&#237;culos); ri&#241;ones (en vasos); intestinos (musculatura lisa de la pared y vasos); tiroide (en vasos).</p>
      <fig id="fig03-body3">
        <graphic xlink:href="1678-4170-abc-93-05-0569-00020-gf03-es.jpg"/></fig>
      <fig id="fig04-body3">
        <graphic xlink:href="1678-4170-abc-93-05-0569-00020-gf04-es.jpg"/></fig>
      <p>Se investig&#243; la m&#233;dula &#243;sea por la posibilidad de discrasia plasmocit&#225;ria y se constat&#243; infiltraci&#243;n acentuada por plasm&#243;citos, moderadamente y bien diferenciados, totalizando cerca del 80% de los elementos celulares. El estudio inmunohistoqu&#237;mico con anticuerpos para cadenas leves kappa y lambda, revel&#243; el perfil monoclonal lambda de la infiltraci&#243;n plasmocit&#225;ria presente en la m&#233;dula &#243;sea (<xref ref-type="fig" rid="fig05-body3">Figura 5</xref>). Se observaron a&#250;n &#233;mbolos de c&#233;lulas plasmocit&#225;rias en vasos de los pulmones, que podr&#237;an corresponder a la leucemizaci&#243;n. Adem&#225;s de ello, los ri&#241;ones presentaban las alteraciones descriptas en casos de mieloma m&#250;ltiple, con superf&#237;cie renal difusa y finamente granulosa y, en la histolog&#237;a, numerosos cilindros hialinos o finamente granulosos, en t&#250;bulos de la m&#233;dula renal. A estos hallazgos estaban todav&#237;a asociadas alteraciones de ex&#225;menes laboratoriales (anemia normoc&#237;tica normocr&#243;mica, aumento de creatinina y proteinuria).</p>
      <fig id="fig05-body3">
        <graphic xlink:href="1678-4170-abc-93-05-0569-00020-gf05-es.jpg"/></fig>
      <p>Otros hallazgos de menor importancia para el cuadro cl&#237;nico fueron un hemangioma hep&#225;tico, con 1,5 cm y ateromasia discret&#237;sima de la aorta.</p>
      <p>Como causa terminal del &#243;bito se observ&#243; tromboembolismo pulmonar derecho, con trombo&#233;mbolo en arteria lobar, con extensa &#225;rea de hemorragia en lobo inferior derecho, y consecuente shock cardiog&#233;nico, con edema cerebral (1240g), con leve achatamiento de giros en la convexidad y herniaci&#243;n de am&#237;gdalas cerebelares.</p>
      <p>
        <bold>Dra. Jussara Bianchi Castelli</bold>
      </p>
      <p>
        <bold>Diagn&#243;sticos anatomopatol&#243;gicos</bold>
      </p>
      <p>Neoplasia maligna de c&#233;lulas plasmocit&#225;rias lambda en la m&#233;dula &#243;sea, asociada a dem&#225;s alteraciones anatomopatol&#243;gicas y laboratoriales, consistente con el diagn&#243;stico de mieloma m&#250;ltiple, incluyendo amiloidosis primaria o amiloidosis sist&#233;mica AL, con dep&#243;sitos en coraz&#243;n (acentuado), pulmones, bazo, ri&#241;ones, trato digest&#243;rio y tiroide; tromboembolismo pulmonar a la derecha; shock cardiog&#233;nico; hemangioma hep&#225;tico; aterosclerosis leve de la aorta.</p>
      <p>
        <bold>Dra. Jussara Bianchi Castelli</bold>
      </p>
      <p>
        <bold>Coment&#225;rios</bold>
      </p>
      <p>La amiloidosis es un proceso asociado a m&#250;ltiples enfermedades que tienen en com&#250;n la deposici&#243;n de prote&#237;nas de aparencia similar (naturaleza f&#237;sica semejante), con variable rompimento estructural y funcional del &#243;rgano comprometido por el dep&#243;sito <sup>30,31</sup>. En la microscop&#237;a electr&#243;nica, cristalograf&#237;a de rayos X y espectroscopia infrarroja, la estructura fibrilar es id&#233;ntica en todos los tipos de amiloidosis, y el amiloides constitu&#237;do de prote&#237;nas fibrilares (95%) y de glicoprote&#237;nas (5%). Se distingue, sin embargo, en cuanto a su naturaleza qu&#237;mica, que incluye 15 formas bioqu&#237;micas distintas, son tres las m&#225;s comunes: AL, AA y Ap<sup>31</sup>.</p>
      <p>La forma AL (amiloides de cadena leve), la m&#225;s com&#250;n de amiloidosis, est&#225; conformada por fragmentos de cadenas leves de inmunoglobulinas. Ocurre entre el 5% y el 15% de los pacientes con mieloma m&#250;ltiple y tambi&#233;n en pacientes sin mieloma: estos &#250;ltimos tendr&#237;an aumento en el n&#250;mero de plasm&#243;citos en la m&#233;dula &#243;sea (discrasia plasmocit&#225;ria), que son las llamadas gammapat&#237;as monoclonales, disproteinemias o paraproteinemias. Por lo tanto, la amiloidosis AL puede estar presente en condiciones malignas (como en el presente caso), benignas o pre-malignas. En este tipo, el linf&#243;cito B maduro en proliferaci&#243;n monoclonal produce un &#250;nico tipo de inmunoglobulina, que se deposita. En la amiloidosis primaria, cerca del 80% de los pacientes tienen solamente la inmunoglobulina monoclonal, la mayor&#237;a lambda, con la plasmocitosis medular modesta, el 20%, mieloma m&#250;ltiple<sup>30,31</sup>.</p>
      <p>La forma AA est&#225; relacionada a un derivado de la prote&#237;na plasm&#225;tica SAA (del ingl&#233;s 'serum amyloid associated protein'), producida en el h&#237;gado para auxiliar la fagocitosis por macr&#243;fagos. Ocurre en la vigencia de enfermedades inflamatorias cr&#243;nicas, tales como lepra lepromatosa, tuberculosis, osteomielitis, bronquiectasias, y artritis reumatoidis, con duraci&#243;n de a&#241;os<sup>31</sup>.</p>
      <p>La forma A&#946; se encontra en la enfermedad cerebral (placas) y en vasos de la lesi&#243;n de Alzheimer. Adem&#225;s de esto, hay tambi&#233;n la ATTR (derivada de la transtiretina o pre albumina), prote&#237;na plasm&#225;tica que transporta tiroxina y retinol (vitamina A), que est&#225; presente en grupos de dist&#250;rbios gen&#233;ticamente determinados (familiar) y en el dep&#243;sito encontrado en el coraz&#243;n de adultos mayores (amiloidosis sist&#233;mica senil), entre otras formas que no se detallar&#225;n aqu&#237;<sup>31</sup>.</p>
      <p>En cuanto al diagn&#243;stico de la amiloidosi, este depende de la identificaci&#243;n morfol&#243;gica del amiloides en muestras de tejido apropiadas y observadas en la microscopia &#243;ptica<sup>31,32</sup>. En la sospecha cl&#237;nica, el primer paso ser&#237;a la demostraci&#243;n del dep&#243;sito amiloides y viene siendo utilizada la bi&#243;psia de grasa abdominal<sup>33,34</sup>, que es positiva en el 85% de los casos de amiloidosis AL<sup>33</sup>. Una vez detectado el dep&#243;sito sospechoso, que se caracteriza por material amorfo y eosinof&#237;lico claro en el tejido, este se debe analizar con tinci&#243;n de rojo-Congo, idealmente en cortes de 10 &#181;m de espesor. Esta tinci&#243;n, de positiva, resultar&#225; en tonalidad roja, en la luz normal, y verde-manzana o verde-botella a la luz polarizada. A partir de ah&#237;, la investigaci&#243;n del tipo de amiloides debe proseguir conforme algoritmo ya establecido<sup>33</sup>. Si no hay historia familiar, se piensa primeramente en el tipo AL que abarca la mayor&#237;a de los casos. As&#237;, la investigaci&#243;n sigue con la b&#250;squeda de discrasia plasmocit&#225;ria a trav&#233;s de la investigaci&#243;n proteica por inmunofijaci&#243;n de la sangre &#243;sea y orina, adem&#225;s de la m&#233;dula &#243;sea. La inmunofijaci&#243;n, que sustituye la t&#233;cnica de inmunoelectroforese por ser m&#225;s sensible y r&#225;pida, combina las t&#233;cnicas de electroforesis e inmunoprecipitaci&#243;n, que por la interacci&#243;n ant&#237;genoanticuerpo aumenta la capacidad de identificar las imunoglobulinas espec&#237;ficas mediante el uso de anticuerpos espec&#237;ficos. La bi&#243;psia de m&#233;dula &#243;sea se debe estudiar con empleo de inmunohistoqu&#237;mica para las cadenas leves kappa y lambda. Si las investigaciones son negativas, la investigaci&#243;n debe seguir hacia las dem&#225;s formas<sup>33</sup>. La determinaci&#243;n del tipo de amiloides es necesaria, ya que el tratamiento, adem&#225;s de soporte de acuerdo con el &#243;rgano afectado, debe dirigirse hacia la causa b&#225;sica para la reducci&#243;n o parada de la deposici&#243;n amiloides<sup>33-35</sup>, siendo a&#250;n la inhibici&#243;n de la formaci&#243;n de las fibrillas amiloides y drogas antiamiloide con acci&#243;n proteol&#237;tica, dos otros blancos de tratamiento todav&#237;a en estudio<sup>34,35</sup>.</p>
      <p>El pron&#243;stico se reserva en la amiloidosis generalizada del tipo AL, con sobrevida de 1 a 2 a&#241;os<sup>33</sup>. Hay mejora de la evoluci&#243;n con la utilizaci&#243;n combinada del transplante aut&#243;logo de m&#233;dula &#243;sea y la quimioterapia<sup>4,35</sup>. En la sist&#233;mica reativa (AA), el pron&#243;stico es dependiente del disturbio subyacente<sup>33</sup>.</p>
      <p>
        <bold>Dra. Jussara Bianchi Castelli</bold>
      </p>
      <p>
        <bold>Referencias</bold>
      </p>
    </body>
  </sub-article>
</article>
